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Chapter 1: 
General introduction 

Preface 
The presence of autoantibodies in patient serum is one of the hallmarks for 
autoimmune diseases. In some diseases the presence of certain autoantibodies is of 
diagnostic significance and the detection and measurement of autoantibodies may therefore 
be of help in the selection of a proper treatment and management of the disease. 
Alternatively, autoantibodies can be used as a tool for the characterization of the 
autoantigens in most cases complicated nucleic acid-protein complexes with important 
cellular functions. It is believed that the elucidation of the structure and function of 
autoantigens may help to understand some of the events causing the aberrant immune 
response to self components. 
Outline of this thesis 
In this thesis autoantibodies directed against the Ro and La ribonucleoprotein 
(RNP) complexes were studied. Both the presence of anti-Ro and anti-La autoantibodies 
in patient sera and the diagnostic relevance of their presence is discussed. In addition, the 
molecular composition of the Ro (SS-Α) and La (SS-B) ribonucleoprotein particles is 
examined, as well as the interactions occurring in Ro complexes, reconstituted in vitro. 
In Chapter 2 an overview is given concerning both the molecular nature and the 
antigenicity of the Ro and La ribonucleoproteins based upon current knowledge. 
To study the composition of Ro RNP complexes it is essential to be assured of 
the monospecificity of the antisera used in the experiments. Therefore, in Chapter 3 a 
new sensitive method is described to analyze patient sera for the presence of anti-Ro and 
anti-La antibodies. 
Chapter 4 deals with the detection of one of the components of Ro RNP 
complexes, the 52 kDa Ro protein, and its involvement in Ro particles m vivo. The 
presence of anti-Ro60 and anti-Ro52 antibodies is analyzed by immunoblotting and the 
association with RNA and intracellular localization of the Ro proteins is examined. 
Moreover, the evolutionary conservation of the antigens is studied by Western blotting. In 
the Appendix of this chapter the evolutionary conservation of the Ro RNAs is analyzed 
as well. 
By various in vitro reconstitution techniques, the molecular composition of the 
Ro RNP complexes has been analyzed in Chapter 5 and Chapter 6, as well as the RNA-
protein and protein-protein interactions occurring in the complexes. 
The results of the studies described in this thesis are summarized in Chapter 7. 
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Chapter 2: 
Ro (SS-Α) and La (SS-B) ribonucleoprotein complexes: Structure, 
function and antigenicity. 
R.L. Slobbe, G.J.M. Pruijn and W.J. van Venrooij 
Annales de Médecine Interne (1991) in press 

Introduction 
During the last decade a great deal of information concerning the Ro and La 
ribonucleoprotein (RNP) complexes has been obtained. For studies on the structure and 
function of these RNA-protein complexes autoantibodies directed against the Ro and La 
antigens, frequently found in patients with systemic lupus erythematosus (SLE) and 
Sjogren's syndrome (SS), have been of great importance. Reversely, the analysis of the 
RNPs and the cloning of the antigens has been and will be of great importance for the 
understanding of the immunological basis of autoimmunity. In this review results 
concerning both the molecular composition of Ro and La RNPs and the pathogenic and 
diagnostic significance of the occurrence of anti-Ro and anti-La autoantibodies will be 
discussed. 
Historical background 
In 1961, Anderson and co-workers described two immunologically distinct 
antibody systems in sera from patients with Sjogren's syndrome, SjT and SjD (Harley, 
1987). A few years later, Reichlin and coworkers demonstrated two distinct precipitin 
systems, designated Ro and La, in sera from patients with SLE (Clark et al., 1969; 
Mattioli and Reichlin, 1974). The similarity in physical and serological properties 
suggested that SjD corresponds to the Ro and SjT to the La antigen. Later on, Alspaugh 
and Tan (1975) reported two new antibody specificities in sera from patients with SS, 
called SS-Α and SS-B, whereas Akizuki et al. (1977) detected a precipitating antibody in 
sera from patients with primary SS and SLE with SS, which was termed Ha. In 1979, 
comparison of all data showed that SS-Α corresponds to the Ro (SjD) antigen and SS-B 
and Ha to the La (SjT) antigen (Alspaugh and Maddison, 1979). 
Structure of La RNPs 
La RNPs are composed of a 46.7 kDa antigenic phosphoprotein (hereafter 
referred to as La) associated with an RNA polymerase III transcribed RNA molecule. The 
RNA moiety of the complex includes (precursors of) 7S RNA, 5S rRNA, tRNA, U6 
RNA and the Ro RNAs as well as some virally encoded RNAs like VA, and VA
n
 RNAs, 
EBERl and EBER2 RNAs (all RNA polymerase III transcripts) and leader RNAs of 
vesicular stomatitis virus and rabies virus (transcribed by virus-specific RNA 
polymerases) (reviewed by Pruijn et al., 1990). In addition, Ul RNA, an RNA 
polymerase Π transcript has been reported to associate with La as well (for review see 
Keene et al., 1987). It has been shown that a З'-uridine stretch common to all RNA 
polymerase ΠΙ transcribed RNAs constitutes the La binding region of the RNA (Stefano, 
1984; Matthews and Francoeur, 1984; Glickman et al., 1988). Since this 3' sequence 
motif is mostly lost upon maturation of the transcripts, the La protein in most cases binds 
to precursor-RNAs only transiently. However, the Ro RNAs and the virally encoded VA 
and EBER RNAs contain the La binding region in the mature RNA and, therefore, the La 
protein is considered to bind to these RNAs in a more stable manner. 
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Structure of the La protein 
Complementary DNA clones encoding the complete La protein have been isolated 
by several groups (Chambers et al., 1988; Chan et al., 1989a). The human La protein is 
composed of 408 amino acids with a predicted molecular weight of 46.7 kDa and is well 
conserved during evolution as revealed by a high degree of amino acid conservation 
between human, bovine and Xenopus laevis La cDNA clones (Chan et al., 1989a; Moreau 
et al., 1990) and by the fact that La proteins from many different species are 
immunoreactìve with human autoantibodies (Chan and Tan, 1987a). Analysis of genomic 
clones revealed that the La gene is split into 11 exons. The promoter region resembles 
that of "housekeeping" genes (i.e. it contains a CCAAT box and an SPI binding 
sequence, but lacks a TATA-box), and contains a G/C rich region that is similar to a 
region in the H-ras gene promotor (Chambers et al., 1988). 
The La protein contains an 80 amino acids domain, termed RNA recognition 
motif, RNA binding domain or RNP-80 motif, often found in RNA binding proteins 
(Bandziulis et al., 1989; Query et 
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the susceptibility of the La protein to 
characteristic degradation products of 43 and 28 kDa (Habets et al., 1983) 
al., 1989; Scherly et al., 1989) and 
shown to be essential for RNA-
binding of a number of proteins. 
Results reported by Chan and Tan 
(1987b) indicate that the RNA 
binding region of La is located at 
the amino terminal part of the 
protein, consistent with the location 
of the RNP-80 motif. Although it is 
presumed that this motif is important 
for the binding of La to the cognate 
RNAs, it has been shown that 
additional sequences at the amino-
terminus of the La protein are 
required for the interaction with 
RNA as well (Moreau et al, 1990; 
our unpublished results). Other 
structural features of La include an 
α-helical central domain, three so-
called PEST-regions, known to be 
susceptible to protease digestion 
(Chan et al., 1989a) and two 
presumed ATP binding sites (Figure 
1). The PEST regions may explain 
proteolytic degradation, often leading to 
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Function of La RNPs 
Because of the apparent loose association of the La antigen with intracellular 
structures, leading to altered distributions in the cell during biochemical fractionation or 
fixation, the intracellular localization of the La antigen has been the subject of extensive 
research and confusion. However, during the past decade it has become evident that the 
La antigen is primarily located in the nucleus as detected by light (Hendrick et al., 1981; 
Habets et al., 1983; Bachmann et al., 1986) and electron microscopic techniques (Carmo-
Fonseca et al., 1989). This localization and the association with newly synthesized RNA 
polymerase III products led to the suggestion that La participates in the transcription, 
maturation and/or nuclear export of the transcripts. Indeed, Gottlieb and Steitz (1989a,b) 
demonstrated that La is required for efficient and correct termination of RNA polymerase 
ΠΙ transcription. Furthermore, it was published that purified La protein may function as 
an ATP dependent helicase able to melt RNA-DNA hybrids (Bachmann et al., 1990a), 
thereby resembling the prokaryotic transcription termination factor rho. However this 
finding has not been confirmed yet. Another putative role for La may be its involvement 
in nucleocytoplasmic transport of the RNA polymerase ΠΙ transcripts (Bachmann et al., 
1989), although it has been shown recently that La is not involved in the transport of 
precursor 5S rRNA from the nucleus to the cytoplasm in Xenopus laevis oocytes (Guddat 
et al., 1990). 
Structure o/Ro RNPs 
Ro RNPs are comprised of several Ro proteins (Table I) complexed with a subset 
of La associated RNAs, the RNA polymerase ΠΙ transcribed Y RNAs. Since the Y RNAs 
are presumably not subjected to processing (Wolin and Steitz, 1983), the La binding 
region of these RNA molecules is present in the mature RNAs and, therefore, the La 
protein can be considered a more stable component of Ro RNPs (Mamula et al., 1989a; 
Boire and Craft, 1990). In human cells, four RNAs have been identified, termed hYl, 
hY3, hY4 and hY5, varying in length between 84 and 112 nucleotides (Hendrick et al., 
1981). The sequences have been determined (Wolin and Steitz, 1983; Kato et al., 1982; 
O'Brien and Harley, 1990) and the derived secondary structures of the RNAs are shown 
in Figure 2. These are characterized 
by base-pairing of the 3' and 5' 
TabUI RoRNP components. ^ ¡ ^ ^
 f o r m i n g ^ ^ ^ 
Ro associated RNAs stem-loop structure. The lower part 
Ü3Í' ï ^ ' Ï3?' ÏZ5. î u m a n ! o f the stem of all hY RNAs contains 
bYl, bY2, bY3, bY4 (bovine) 
cYi, cY3, cY4, cY5 (cava) a highly conserved region which has 
lYi, 1Y2,1Y3 (leporine) been shown to be protected against 
rYlA, rYlB, rY2 (rat)
 тахтА
 . . . .
 ηΎ7 .. . 
mYi.mY2 (murine) ™Ase ¿egradaüon (Wohn and 
dYi, dY2 (duck) Steitz, 1984), presumably by bound 
protein(s). 
Ro asBociated protein» 
60 kDa (=Ro60)> 52 kDa (=Ro52) (ubiquitous) The Ro RNPs show hetero-
60 шв, 54 Ша (eiythrocytes) geneity at several levels. First, the 
и
 total number of cellular Ro RNAs 
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Figure 2 Human Ho RNAs 
Predicted secondary structures of hYl, hY3, hY4 and hY5 based upon bee energy minimizations using parameters 
of Turner et al., 1988. The structures of hY3 and hY4 were slightly modified with minor effects on free energy of 
formation to maintain a constant structure of the most conserved region. At the 3' end of hY4 a undine residue was 
added in order to rescue the La binding region of hY4 RNA. Most highly conserved regions are boxed Similar 
structures have been published by Wolin and Slcitz (19(3). O'Brien and Натку (1990) and Pmijn et al. (1990). 
differ among species, varying from two in mouse and duck cells to four in human, bovine 
and guinea pig cells (see Table I)(Hendrick et al., 1981; Reddy et al., 1983; Mamula et 
al., 1989b; Itoh et al., 1990). An RNA of similar size as hYl RNA has been found in all 
species analyzed as detected by analysis of anti-Ro immunoprecipitated RNAs, whereas Y 
RNAs homologous to hYl and hY3 have been detected by Northern blotting in all 
mammalian cells examined (our unpublished results). 
Second, differences in Ro RNP composition have been observed between cells 
within a species. In human red blood cells only hYl and hY4 RNA are immuno­
precipitated (Rader et al., 1989; O'Brien and Harley, 1990) in contrast to the four RNAs 
found in other human cells. Moreover, two antigenic Ro proteins of 60 and 54 kDa have 
been detected in red blood cells (Rader et al., 1989), while in other human cells 60 kDa 
(Ro60, antigenically distinct from the red blood cell 60 kDa protein) and 52 kDa (Ro52) 
antigens have been described (Ben-Chetrit et al., 1988). Additionally, a third 
immunoreactive 60 kDa protein has been described in Wil-2 cells (Lieu et al., 1988). 
This protein was shown to be homologous to a number of calcium binding proteins 
(McCauliffe et al., 1990) but the evidence concerning its role as a Ro RNP component, 
however, is as yet doubtful. In fact, in follow-up studies no evidence has been obtained to 
confirm the association of this 60 kDa protein with Ro RNP complexes (Dr L. Rokeach, 
personal communication; our unpublished results). 
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Third, within a cell different Ro RNPs 
can be distinguished based upon different 
physicochemical properties (Boire and 
Craft, 1990). The molecular weights of 
the Ro complexes as estimated by gel 
filtration were quite heterogeneous: Ro 
RNP complexes were found at 230 kDa 
(containing hY4 RNA only) and between 
300 and 350 kDa (one subset of RNP 
particles containing hYl, hY3 and hY4 
RNA and one containing hY5 RNA only). 
These unexpectedly high molecular 
weights may be explained by the existence 
of multimers of proteins or particles or 
may be due to the differential binding of 
yet unidentified Ro components. A further 
indication for the heterogeneity of Ro 
RNPs within the cell is the detection of a 
human antiserum precipitating hY5 RNA 
only, thus indicating that the hY5 RNP 
particle contains unique antigenic 
determinants (Boire and Craft, 1989). 
Results from our laboratory have 
identified some of the interactions 
occurring in Ro RNP complexes. As summarized in Figure 3, no direct interactions 
between the two Ro antigens and the La antigen could be observed, indicating an 
independent binding of the Ro and La antigens to the h Y RNA. Binding of Ro52 to h Y 
RNA, however, was found to be dependent on the presence of Ro60. A direct RNA-
independent protein-protein interaction between Ro60 and RoS2 has been identified in 
which a region of Ro60 between amino acid 276 and 318 was required for the binding of 
Ro52. Additionally, the presumed binding regions of the Ro proteins (the conserved 
nucleotides in the lower part of the stem of the RNA) and La (the 3' uridine stretch) on 
hY RNAs were indeed shown to be the sites of interaction of these proteins (Slobbe et 
al., submitted; Pruijn et al., manuscript in preparation). 
The evolutionary conservation of the Ro antigen has been the subject of several 
studies. Ro RNPs have been detected immunologically in a number of species, such as 
man, monkey, dog, cat, guinea pig, bull, rabbit, rat, mouse and duck (Hendrick et al., 
1981; Mamula et al., 1989b; Byers et al., 1990; Slobbe et al., 1991a). Since most of 
these authors used antisera with mixed specificities and, therefore, could not discriminate 
between Ro60 and Ro52, the evolutionary conservation of Ro60 and Ro52 has not been 
elucidated in detail. Results from our laboratory (Slobbe et al., 1991a) indicate that Ro60 
is well conserved during evolution. In contrast, RoS2 could be detected immunologically 
in primate cells only. Whether this limited conservation of Ro52 reflects the loss of 
Figure 3 Model for the hYl KNP. 
Secondary structure of hYl RNA u shown ая 
predicted by the method of Turner et a l , 1988 
Proteins are shown as filled circles 
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epitopes during evolution or the absence of a related protein is as yet not clear. 
Hopefully, analyses by Northern blotting will answer this question in the near future. 
Structure of the 60 kDa Ro protein 
Two cDNAs encoding R06O have been isolated and characterized (Deutscher et 
al., 1988; Ben-Chetrit et al., 1989). Some differences exist in the 3' sequences of the 
coding regions of the cDNAs (the C-terminal 24 amino acids of the predicted protein 
sequence by Deutscher et al. are replaced by 11 amino acids in the protein deduced from 
the cDNA reported by Ben-Chetrit et al.) leading to molecular weights of 60.6 and 59.2 
kDa, respectively. Whether this difference is caused by alternative splicing of one gene 
product or reflects differential expression of two genes encoding the R06O protein (the 
two cDNAs were obtained from human cells derived from different tissues) is not clear 
yet. The common part of the deduced R06O proteins contains an RNP-80 motif and a 
putative zinc finger (see Figure 1). Although the RNP-80 domain is thought to dominate 
the RNA-R06O interaction, it has become clear that the conformation of R06O is 
extremely important for the binding to h Y RNA since small deletions at the amino- or 
carboxy-terminus of the protein precluded the binding to h Y RNA (Pniijn et al., 
manuscript in preparation). The zinc finger is a cluster of cysteine and histidine residues 
originally described to be involved in the binding of DNA by DNA-binding proteins, but 
possibly involved in RNA-protein or protein-protein interactions as well (Berg, 1986; 
Nelissen et al, 1991). Deutscher et al. (1988) were able to reconstitute ribonucleoprotein 
complexes in vitro composed of hYl RNA and recombinant R06O protein, suggesting a 
direct association of R06O with h Y RNA. 
Structure of the 52 kDa Ro protein 
Ro52 was not detected by Western blotting until recently, because it comigrates 
in SDS-PAGE with the La protein. However, altering the crosslinking level of the 
Polyacrylamide gels enables the separation of the Ro52 and La polypeptides and allows 
their subsequent detection by immunoblotting (Ben-Chetrit et al., 1988; Buyon et al., 
1990; Slobbe et al., 1991a). Recently, two cDNA clones coding for Ro52 have been 
isolated and characterized (Chan et al., 1991; Itoh et al., 1991). Except for some small 
differences, possibly due to DNA sequencing errors, both cDNAs encode a protein with a 
molecular weight of 54.1 kDa. No homology was found with the R06O protein, but a 
significant homology was found with a mouse T-cell down-regulatory protein rpt-1 and 
with human transforming protein rfp. The deduced amino acid sequence and secondary 
protein structure reveal a number of interesting features (Figure 1): First, a number of 
putative zinc finger motifs were found in the amino terminal part of the protein. The 
location, number and spacing of these motifs are highly conserved in the Ro52, φ and 
rpt-1 proteins, which may relate to a similar function for all three proteins. Second, the 
same region of Ro52 where the putative zinc fingers are located contains a consensus 
sequence for a newly identified cysteine-rich motif found in a number of DNA binding 
proteins (Freemont et al., 1991). However, the biological significance of this motif has 
not been defined yet. Third, a leucine zipper motif is present in the central part of the 
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Ro52 protein. Although leucine zippers were originally described in DNA binding 
proteins (Landschultz et al., 1988), these motifs are now known to participate in protein-
protein interaction and dimer formation as well (Kouzarides and Ziff, 1988; Sassone-
Corsi et al., 1988; Landschultz et al., 1989). Therefore, the putative leucine zipper of 
Ro52 may be important for the interaction with other proteins or for dimerization. No 
direct association of Ro52 with Ro RNAs has been found. 
Function of Ro RNP complexes 
Although the intracellular localization is not clear yet, various biological 
functions have been proposed for the Ro RNPs. Among these are nuclear functions such 
as roles in transcription, processing and transport processes, based upon a potential 
nuclear localization and the relation with the La antigen. Because of the observed 
cytoplasmic localization, some cytoplasmic functions have been suggested as well, such as 
translation and storage of processed mRNA. At present, it cannot be excluded that 
different Ro RNPs are involved in different processes and since Ro RNPs seem to be 
reasonably well conserved in evolution, it is likely that these RNA-protein complexes 
support important functions. 
Prevalence of anti-Ro and anti-La autoantibodies 
Autoantibodies directed against the Ro and La antigens can be found in sera from 
patients with a variety of autoimmune disorders (see Table II) but do not seem to be 
completely disease specific. The variance of the numbers mentioned in Table II can be 
explained partly by the use of different methods for the detection of the autoantibodies. 
For example, it is known that anti-Ro antibodies, in contrast to anti-La antibodies, can not 
be detected as sensitive by Western blotting as by counter Immunoelectrophoresis 
(Williams et al., 1986; Meilof et al., 1990; Provost et al., 1991; van Venrooij et al., 
1991). In addition, for the detection of anti-La antibodies a very sensitive RNA 
precipitation assay has been developed by which very low titers of anti-La antibody can 
be detected (Slobbe et al., 1991b). In some cases, "normal" human sera may also contain 
very low titers of anti-Ro antibodies (Gaither et al., 1987). High frequency presence of 
anti-Ro antibodies has been associated with subacute cutaneous lupus (Sontheimer et al., 
1979 and 1982; Provost, 1991) and with neonatal lupus (Provost, 1983; Buyon et al., 
1989; Watson et al., 1991). In neonatal lupus IgG antibody is transplacentally transferred 
from mother to infant and manifested in skin rash and complete congenital heart block. 
However, the pathogenesis of neonatal lupus may not be due to the presence of 
autoantibodies since many mothers with anti-Ro antibodies give birth to normal offspring. 
Since both anti-Ro and anti-La antibodies are most prevalent in sera from patients 
with either Sjogren's syndrome or systemic lupus erythematosus, these two patient groups 
have been studied extensively in order to reveal possible disease associations. In Sjogren's 
syndrome anti-Ro and anti-La antibodies were found more frequently in patients with 
earlier disease onset, longer disease duration, parotid or major salivary gland enlargement 
and intensive lymphocytic infiltrations of the minor salivary glands (Manoussakis et al., 
1986). Additionally, the presence of anti-Ro and anti-La antibodies correlated well with 
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Tabk II The prevaUnet of aittì-Ro ana anti-La antibodies in connective 
tissue diseases. 
Disease1 
SLE 
SS 
RA 
Polymyositis 
Controle 
Method2 
of detection 
ELISA 
Ш 
ID 
CIE 
IB 
CIE, ID 
СШ 
RNA 
ELISA 
CIE, Ш 
ID 
IB 
CIE, ID 
RNA 
ELISA 
ID 
RNA 
ELISA 
ID 
ELISA 
ID 
ELISA 
RNA 
anti-Ro 
(%) 
55 
51 
63 
19-69 
17 
35 
12-28 
n.d. 
96 
63 
83 
38 
60 
n.d. 
28 
15 
n.d. 
18 
9 
5 
2 
17.5 
n.d. 
anti-La 
(%) 
24 
6 
12 
3*41 
10 
15 
18-45 
35 
87 
40 
25 
77 
40 
58 
22 
0 
16 
18 
0 
0 
0 
7.5 
0 
reference 
Maddison et al., 1985 
Yamagatactal., 1986 
Boeyetal., 1988 
Speranskyetal., 1988 
DeRooij et al., 1988 
Chan and Tan, 1989 
Swaak et al., 1990 
Slobbeetal., 1991b 
Harley et al., 1986 
Manoussakis et al, 1986 
Yamagataetal., 1986 
De Rooij et al., 1988 
Chan and Tan, 1989 
Slobbe et al., 1991b 
Maddison et al., 1985 
Yamagataetal., 1986 
Slobbe et al., 1991b 
Maddison et al., 1985 
Yamagata et al., 1986 
Maddison et al., 1985 
Yamagataetal., 1986 
Gaitheretal., 1987 
Slobbe et al., 1991b 
' SLE; systemic lupus erythematosus, SS; Sjogren's syndrome, RA; rheumatoid arthritis 
1
 Ш; immunodiffusion, IB; immunoblotting, СШ; counter immunoelectrophoreais, RNA; RNA precipitation 
other disease manifestations such as purpura, leukopenia, lymphopenia, increased 
polyclonal gamma globulins and reumatoid factor titers (Harley et al., 1986). Both anti-
Ro and anti-La antibody was found in the saliva of SS patients, but it is not clear whether 
these antibodies are produced locally or whether the presence of these autoantibodies in 
saliva was due to leakage from blood towards the saliva (Horsfall et al., 1989; 
Manoussakis et al., 1989), nor has it been demonstrated that the presence of anti-Ro or 
anti-La autoantibody in the saliva accounts for the "dry mouth" syndrome typical for 
patients with Sjogren's syndrome. 
In SLE patients clinical disease manifestations associated with the presence of 
anti-La and anti-Ro antibodies are not identified unambiguously, although some studies in 
this area have been performed. Wasicek and Reichlin (1982) found a strong positive 
correlation of the presence of anti-Ro antibodies alone with serious renal disease. 
However, Maddison et al. (1988) reported a negative correlation of the presence of anti-
Ro antibodies with nephritis, in agreement with Swaak et al. (1990). These latter authors 
also reported a positive correlation of the presence of anti-La antibodies with central 
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nervous system involvement. Additionaly, both Wasicek and Reichlin (1982) and 
Speransky et al. (1988) reported a positive correlation of the presence of both anti-Ro and 
anti-La antibodies in SLE patients with skin rash. 
Since most of the studies mentioned above could not discriminate between anti-
R06O and anti-Ro52 antibodies, only few information on the presence of these two 
autoantibodies in patient sera is available. Ben-Chetrit et al. (1990) and Slobbe et al. 
(1991a) reported the presence of both anti-Ro60 and anti-Ro52 antibody in SLE and SS 
patient sera. The presence of anti-Ro60 alone, however, was indicative for SLE, whereas 
the presence of anti-Ro52 alone was indicative for Sjogren's syndrome. In neonatal lupus, 
the predominant anti-Ro antibody response was found to be directed to the Ro52 antigen 
(Buyon et al., 1989), often accompanied by the presence of anti-La antibody. Clinical 
manifestations in SLE and SS patients associated with the presence of anti-Ro60 or anti-
Ro52 antibodies have not been reported yet. 
Autoepitopes on Ro and La antigens 
Autoepitopes of the La protein have been described by many authors using 
different biochemical and molecular biological approaches (summarized in Figure 4). In 
1986, Chan and co-workers described the presence of autoepitopes on two domains of the 
La protein obtained by limited proteolytic cleavage, designated X (29 kDa) and Y (23 
kDa), later identified as the N- and C-terminal part of the La protein, respectively. The 
cloning of (part of) the cDNA encoding La has facilitated the characterization of B-cell 
epitopes considerably. By cloning of the carboxy-terminal end of La, Sturgess et al. 
(1988) showed that an 
epitope was located in a 
N ^ ^ — ^ 1 I ^ ^ — ^ ^ ^ — С region between amino 
1
 RNP-eo 4 0 e acid (aa) 306-408. Rauh 
^ — Chamtwra at al. 1966 
et al. (1988) identified 
three B-cell epitopes 
Rauh ai aL »ее located at the C-terminus 
of La between aa. 224-
292, aa. 293-345 and aa. 
346-380, respectively. 
Since in this study every 
anti-La antiserum tested 
κ.»...!» .t .ι mo contained antibodies to 
Μ.,Ν.11... .· .1. IMO all three epitopes at a 
ι lor a4a 401 ., ,. ,. 
similar ratio, the sug­
gestion was made that 
Figure 4 AutatpitoptsofLa. the production of anti-La 
Schematic representation of autoeprtope» of the La protein, as deaenbed by . . . 
the authora indicated on the right. Solid ban represent major epitopes, autoant ibodies i s ant igen 
dashed bars epitopes of intermediate importance, open ban epitopes of low dr iven. В Y analvSÏS o f 
significance. Number« refer to the number« of the amino acids of La. , . . . , . 
Asterisks mean that only partial La cDNAs were used in the determination m e antigenicity 01 Ше 
of autoepitopes of the La proton. Complete La protein 
Bluroaaa at al. I M S 
Chambara at al. 1 M 8 
Chan at al. 1М9Ь 
Bini at al. IMO 
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using recombinant protein, an epitope in the N-terminal region of the La protein was 
identified (termed A: aa. 1-107) in addition to epitopes in the middle of the protein 
(termed C: aa. 111-242) and at the C-terminus at aa. 242-408 (termed D; Chambers et 
al., 1988; St. Clair et al., 1988; McNeilage et al., 1990). St. Clair et al. (1990a) showed 
by analysis of sequential sera that antibody responses to these different epitopes (А,С and 
D) vary in parallel over time both in Sjogren's syndrome and in SLE patient sera, 
indicating a coordinated expression of different anti-La antibody populations. In 1989, 
Chan and coworkers (1989b) described preliminary results concerning the presence of two 
autoepitopes on La, located at aa. 76-112 and at aa. 280-408. Recently, Bini et al. (1990) 
described two immunodominant epitopes located at aa. 112-226 and aa. 226-408, whereas 
Kohsaka et al. (1990) identified two major epitopes at aa. 81-101 and aa. 283-338 and a 
minor epitope at aa. 179-220. Up till now, no clinical manifestations of autoimmune 
patients could be linked to the presence of autoantibodies to specific epitopes on La 
(St.Clair et al., 1989), suggesting that the quantitative and qualitative aspects of the anti-
La immune response are determined by factors distinct from those determining the clinical 
expression of disease. 
Virtually nothing is known about the location and significance of autoepitopes of 
Ro52 and Ro60. Preliminary results indicate that autoepitopes are located along the entire 
length of Ro60 (Saitta et al., 1989). 
Onset and perpetuation of the autoimmune response 
One can only speculate on the mechanisms governing the autoimmune response 
to the La antigen. Generally it is believed that the autoimmune response is driven by the 
antigen itself, as indicated by the multiplicity of the epitopes on the antigens found in 
most sera, the coordinated expression of different anti-La antibody populations (St. Clair 
et al., 1989) and the preferred reactivity of human autoantibodies with human antigens 
(Reichlin et al., 1989; Reichlin and Reichlin, 1989; Provost et al., 1991). However, it is 
not clear whether the antigen itself is involved in the onset of the immune response. By 
immunization with La protein, it was shown that the immune response to La in mice is 
different from the autoimmune response in man (St. Clair et al., 1990b). This may be due 
to differences in the immune system of mice compared to man, but, alternatively, may be 
explained by the fact that the La protein itself is not involved in the onset of the immune 
response. In addition, a striking homology between an autoimmune epitope of La 
(between aa. 81-101) and a viral gag protem has been noticed (Kohsaka et al., 1990) and 
it has been shown that immunodominant epitopes of the НГ capsid protein are located in 
the regions with high similarity to epitopes found in a number of autoantigens, among 
which is the N-terminal epitope located between aa. 81 and 101 of La (Garry, 1990). 
Furthermore, McNeilage et al. (1990) detected a primary reaction against an 
immunodominant epitope of the La protein located at aa. 1-107 which in a later stage of 
the disease was followed by the appearance of other antibody classes recognizing other 
epitopes. This may indicate that the onset of the autoimmune response is indeed directed 
against the N-terminus of the La protein, which includes the epitopic region with high 
homology to a viral protein (Kohsaka et al., 1990). Therefore, an interesting hypothesis is 
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that the autoimmune response to the La protein is invoked by cross-reaction of antibodies 
originally directed against a viral protein (molecular mimicry). 
However, other models for the onset of the immune response to the La antigen 
have been proposed. For example, it has been observed that the La antigen is able to 
translocate to the cell membrane after virus infection or UV-irradiation (Baboonian et al., 
1989; Bachmann et al., 199(A); Furukawa et al., 1990). After translocation to the cell 
surface the La antigen might be exposed to the immune system and after binding to HLA 
class Π proteins an autoimmune response might be induced. In this model the antigen 
itself (or parts of the antigen) is responsible for the onset of the immune response. 
Perspectives 
As will have become clear, in spite of the fact that a great deal of knowledge has 
become available in the last decade, a lot of intriguing questions still remain to be 
answered. We have to know more about the structure, function and antigenicity of the Ro 
and La RNP complexes to be able to answer more fundamental questions about the 
molecular basis of autoimmunity. It is expected that the molecular cloning of the RNP 
components will provide further tools for tackling these problems and that further 
research will help us to understand better the molecular basis of autoimmunity. 
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Abstract 
Upon infection of HeLa cells with adenovirus type 5 the cellular La protein becomes 
predominantly associated with the virally encoded RNA polymerase III products VAl and 
VA
n
, while most of the host RNA polymerase II (e.g. Ul, U2, U4, U5 and mRNA) and 
RNA polymerase III transcription (e.g. U6 and pre-tRNAs) is stopped. Interestingly the 
cellular Ro RNAs, RNA polymerase HI products as well, are still being transcribed and 
assembled into ribonucleoprotein complexes containing the Ro (SS-Α) antigen. 
Using a pPJ puke-chase labelled, adenovirus infected HeLa cellular extract as a source 
of antigen, anti-La (SS-B) and anti-Ro (SS-Α) antibodies can be detected simultaneously 
using an immunoprecipitation assay. It is shown that this method is more sensitive in 
detecting anti-La antibodies then counter Immunoelectrophoresis and immunoblotting. 
Because of the sensitivity of the method, the percentage of sera from patients suffering 
from rheumatic diseases positive for anti-La antibody is raised significantly, especially in 
patients with systemic lupus erythematosus. 
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Introduction* 
The La protein, also called SS-B antigen (Alspaugh et al., 1979, Provost, 1979, 
Lemer et al., 1981a), is a highly conserved 47 kDa phosphoprotein. Mammalian cells 
contain approximately 2 * 10 7 copies of this protein. La is predominantly localized in the 
cell nucleus and forms tight complexes with newly synthesized RNA polymerase Ш 
transcripts (for review, see Pruyn et al., 1990). Some abundant viral small RNA 
transcripts are also known to be associated with the La protein, among which the VA I 
and VA II RNAs of adenovirus (Lemer et al., 1981a, Rosa et al., 1981, Francoeur et al., 
1982), the EBER 1 and EBER 2 RNAs of Epstein-Вагг virus (Lemer et al., 1981b) and 
the leader RNAs of vesicular stomatitis virus (Wilusz et al., 1983) and rabies virus 
(Kurillaetal., 1984). 
The Ro (SS-Α) ribonucleoprotein (RNP) particle in human cells consists of at 
least two antigenic proteins of 60 and 52 kDa complexed with four RNAs, termed hYl, 
hY3, hY4 and hY5. These RNAs are known to be transcribed by RNA polymerase ΙΠ 
and are therefore associated with the La protein as well. The exact molecular 
composition, cellular localization and function of the Ro ribonucleoprotein complexes is 
still unknown (Pruyn et al., 1990). 
For some reason, the La and Ro proteins can become targets of the immune 
system in several autoimmune syndromes, often leading to the occurrence of both anti-La 
and antí-Ro autoantibodies in patients (for review, see Tan, 1989). Many studies have 
pointed to the diagnostic value of anti-La and anti-Ro autoantibodies in serum of patients 
suffering from connective tissue diseases. In these studies up to 40% of Sjogren's 
syndrome (SS) patients, 10-15% of systemic lupus erythematosus patients (SLE)(de Rooij 
et al., 1988, Chan et al., 1989), 31% of undifferentiated connective tissue disease 
(UCTD) patients and 6% of rheumatoid arthritis (RA) patients (de Rooij et al, 1988) were 
found to have anti-La antibodies, whereas about 60% of SS, 35% of SLE (Chan et al, 
1989), 11% of UCTD and 2% of RA (de Rooij et al., 1988) patients were positive for 
anti-Ro antibodies. However, these figures are mainly based upon the detection of 
antibodies by conventional immunological methods such as immunoblotting, counter 
Immunoelectrophoresis (CIE) and ELISA, that all have their respective pro's and 
contra's. Immunoblotting is known for its sensitivity but detection may be negatively 
influenced due to the disruption of conformational epitopes. Counter 
Immunoelectrophoresis is very simple but not as sensitive and very dependent on the 
quality and source of antigen used in the assay. The ELISA method is very rapid, 
sensitive and easy to handle, but can be used only when purified antigens are available. 
Since monoclonal antibodies directed against the Ro and La proteins are still 
'Abbreviations: RNP: ribonucleoprotein saRNA: small nuclear RNA SS: Sjogren's 
syndrome UCTD: undifferentiated connective tissue disease RA: rheumatoid arthritis 
CIE: counter immunoelectrophoresis VA RNA: adenovirus associated RNA nijG: 
N^.N^N'-trimethylguanosine 
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relatively rare, human sera containing autoantibodies against these components are widely 
used in studies on the function, composition and localization of Ro and La 
ribcnucleoprotein complexes. For this type of study it is essential to be assured of the 
monospecificity of the human autoantibody. Using adenovirus infected HeLa cell extracts 
as the source of antigen in an immunoprecipitation assay, the VA RNAs precipitated by 
patient sera are highly indicative for the presence of anti-La antibodies, whereas the Ro 
RNAs, precipitated by anti-Ro antibodies, can be demonstrated simultaneously. Due to 
the large amount of VA RNA produced in these cells and the extreme sensitivity of 
detecting the precipitated ["PJ-labelled VA RNAs, this method is much more sensitive 
than immunoblotting and counter immunoelectrophoresis. Using this method we were able 
to detect low concentrations of anti-La antibody, that seem to be frequently present in 
sera from patients with systemic lupus erythematosus. 
Materials and methods 
Human sera 
Sera were obtained from patients with connective tissue diseases such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS) and 
undifferentiated connective tissue disease (UCTD), all diagnosed according to established 
criteria as described before (de Rooij et al., 1988). 
Infection and labelling of HeLa celL· 
HeLa S3 monolayer cells were infected with adenovirus type 5 at approximately 
100 pfu/cell in Eagles minimal essential medium (EMEM) supplemented with 1 mM 
arginine at about 60% confluency. After 16 h of infection cells were labelled for various 
periods of time with pPJ-orthophosphate (lmCi/10 ml medium) in EMEM supplemented 
with 5% dialysed fetal calf serum and when indicated chased for 7 h in non-radioactive 
EMEM with 5% fetal calf serum. 
Preparation of cellular extract 
The infected and labelled cells were washed once with PBS and harvested in NE-
4 buffer (lOmM Tris-Cl pH7.4, ImM MgCl2, lOOmM NaCl) at 4.0 * 106 cells/ml. After 
sonication of the cells (Branson sonifier; output 3, duty cycle 50%, pulsed, 2 * 1 min.) 
the suspension was centrifuged at 13000g for 10 min at 4 °C. The supernatant was stored 
at -70 "С in aliquots. 
RNA precipitation 
Protein A Sepharose (PAS) beads were prepared for RNA precipitation by 
rotating 250/Л 10% PAS with 20^1 serum in 400/il IPP ( lOmM Tris-Cl pH 8, 0.5M 
NaCl, 0.1% Tween 20, 0.1% NP40) for 1 h followed by washing three times with IPP. 
The PAS beads coated with antibody were subsequently rotated with 125 μΐ cellular 
extract in 400 /tl IPP for 2h at 4 "С. After washing 5 times with 1 ml IPP the PAS beads 
were resuspended in 350 μΐ NET-2 buffer (150mM NaCl, 50mM Tris-Cl pH7.4, 0.05% 
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NP40) containing 0.25% SDS and phenol extracted. After 20 min. RNAs were ethanol 
precipitated using 5μ% carrier tRNA and analysed on a 10% polyacrylaimde-8M Urea gel. 
Preparation ofHeLa S3 cytoplasmic extract and immunoblotting 
HeLa S3 suspension cells were harvested and washed twice with NKM (125mM 
NaCl, 5mM KCl, 1.5mM MgCy and once with hypotonic Hepes buffer (lOmM Hepes 
pH 7.9, lOmM KCl, 1.5mM MgCl2, 0.5mM DTT). After resuspending the cells in 2 
volumes of hypotonic Hepes buffer and incubation on ice for 20 min. the cell suspension 
was homogenized by 10 strokes in a dounce-homogenizer (B-pestle). After addition of 0.1 
volume of isotonisation buffer (0.3M Hepes pH 7.9, 1.4 M KCl, 0.03 M MgClj) the 
extract was centrifuged for 10 min. at 13000g and used for immunoblotting (Towbin et 
al., 1976). 
Counter Immunoelectrophoresis and immunodiffusion 
Counter Immunoelectrophoresis (CIE) was carried out essentially as described 
before (Kurata et al., 1976). Lyophilized rabbit thymus extract (Pelfreez Biologicals, 
Rogers, Arkansa, USA) was used as source of antigen for the determination of anti-La 
and human spleen extract , prepared as described before (Clark et al., 1969), for the 
detection of anti-Ro antibodies. All antigens were made to a final protein concentration of 
5 mg/ml. Reference human sera, monospecific for anti-Ro and anti-La antibodies were 
obtained from CDC, Atlanta, Georgia, USA. 
Results 
Ro, La and U RNA synthesis after adenovirus infection of Hela cells 
When [32P]-orthophosphate labelled Hela cells are used as antigen source, the Ro 
RNAs, termed hYl- hYS, the La RNAs, like pre-5S and pre-tRNAs and the U RNAs can 
be precipitated by patients sera with antibodies directed against their respective antigens ( 
figure 1, panels A,B and C, lanes 1). To examine the turnover and stability of these 
ribonucleoprotein (RNP) complexes, pulse-chase labelling of HeLa cells with [32P]-
orthophosphate was performed. For the Ro RNP complex, the RNAs need about 5-7h to 
associate fully with the Ro (SS-Α) antigens (figure 1, panel A, lanes 2 and 3), as do the 
U RNAs with the Sm antigen (figure 1, panel B, lanes 2 and 3). The La RNAs like pre­
ss and pre-tRNAs become associated to the La (SS-B) antigen directly after transcription 
and are then gradually released (figure 1, panel C, lanes 2 and 3). 
After infection of HeLa cells with adenovirus for 16h, the Ro RNAs are still transcribed 
and become associated with the Ro (SS-Α) antigen (figure 1, panel A, lane 4), in contrast 
to the U RNAs, which are no longer precipitable by Sm sera (figure 1, panel B, lane 4) 
or by anti-n^G-cap antibodies (data not shown). The virally encoded VA RNAs become 
associated with the La (SS-B) antigen with a concomitant decrease of La-host RNA 
complexation (figure 1, panel C, lane 4). Pulse-chase labelling of infected HeLa cells 
reveal that the stability and turnover of the Ro RNP complex is not markedly changed 
after adenovirus infection (figure 1, panel A, lanes S and 6), whereas the binding of VA 
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Fig.l. Precipitation of labeled RNA in uninfected and adenovirus infected HeLa cells. 
RNA precipitation patterns of uninfected (marked mock;lanes 1-3) or adenovirus infected (marked adeno;lanes 
4-6) [''P] orthophosphatc labeled HeLa cellular extracts. In panel A a monospecific anti-Ro (SS-Α) serum, in 
panel В an anti-Sm serum and in panel С a monospecific anti-La (SS-B) serum was used. In lanes 1 and 4 
cells were labeled for 9h, in lanes 2 and S cells were labeled for 2h and in lanes 3 and 6 cells were pulse 
labeled for 2h and chased for 7h with non-radioactive medium. 
RNA to the La protein is quite stable (figure 1, panel C, lanes 5 and 6). 
The use of RNA precipitation for the simultaneous detection of anti-Ro (SS-A) and anti-La 
(SS-B) antibodies using adenovirus infected HeLa cellular extracts 
Because anti-Ro (SS-Α) and anti-La (SS-B) antibodies are often found together in 
patient sera, a system to test sera for anti-Ro and anti-La activity was set up. Since the 
VA RNAs in adenovirus infected cells become strongly associated with the La (SS-B) 
antigen (Francoeur et al., 1982), a [32P]-orthophosphate labelled adenovirus infected HeLa 
cellular extract was used for immunoprecipitation. 
As shown in figure 2, panel A, both monospecific anti-Ro and monospecific anti-
La sera precipitate their cognate RNAs (lanes 2 and 3), but when a serum is used that 
contains both anti-Ro and anti-La antibodies, the Ro RNAs, precipitated by the anti-Ro 
antibodies, are not easily detected because of their comigration with the pre-tRNAs, that 
are precipitated by the anti-La antibodies (lane 4). 
Because of the stability of the binding of VA RNA to the La protein, the relatively fast 
turnover of the pre-tRNA to La protein binding and the slow association of the Ro RNAs 
with the Ro antigen, infected HeLa cells were pulse labelled for 2h and subsequently 
chased for 7h in nonradioactive medium (figure 2, panel B). Monospecific anti-Ro and 
anti-La sera still precipitate the Ro RNAs and VA RNAs respectively (lanes 2 and 3) and, 
moreover, a serum containing both anti-Ro and anti-La antibodies precipitates both VA 
RNA and the Ro RNAs, the latter not being masked any more by other precipitated 
RNAs (lane 4). Therefore in our further experiments, an adenovirus infected HeLa 
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Fig. 2. The effect of pulse-chase labeling on RNA 
precipilation in uninfected and adenovirus infected HeLa 
cells. 
RNA precipitation patterns, 
using normal human serum (lanes 1), 
monospecific anti-Ro serum (lanes 2), 
monospecific anti-La (lanes 3) or an 
anti-Ro/La serum (lanes 4). In panel 
A HeLa cells were infected with 
adenovirus for 16h, labeled with [,2P1 
orthophosphate for 7h and then used 
as antigen source. In panel В HeLa 
cells were infected with adenovirus 
for 16h, labeled for 2h with ["P] 
-orthophosphate, chased for an 
additional 7h with non-radioactive 
medium and then used as a source 
of antigen. 
cellular extract, pulse labelled for 2h with [32P]-orthophosphate and chased for 7h with 
non-radioactive medium, was used to determine the presence of both anti-Ro and anti-La 
antibodies in patient sera. 
To establish the sensitivity of this method for the detection of anti-La antibodies, 
we analysed a number of sera by counter Immunoelectrophoresis (CIE) and 
immunoblotting and compared the presence of anti-La antibodies demonstrated by these 
techniques with the results of the VA RNA precipitation method. As shown in table 1, 
132 randomly selected sera of patients suffering from different connective tissue diseases 
were tested for the presence of anti-La antibodies. Of these 132 sera, 23 were positive for 
anü-La activity in CIE and 24 sera were found positive by immunoblotting. Strikingly, by 
using VA RNA precipitation 22 additional sera were found to contain anti-La antibodies. 
This demonstrates the 
greater sensitivity of the 
VA RNA precipitation 
method for the detection of 
low levels of anti-La 
antibody. To ascertain that 
indeed anti-La antibodies 
were responsible for the 
precipitation of the VA 
RNA, uninfected [32P]-
labelled HeLa cellular 
extract was immunopre-
cipitated with some antisera 
positive for anti-La antibody 
in the VA RNA precipi-
tation assay, but negative by 
TabU I: Comparison of the sensitivity of counter immuno 
electrophoresis (CIE) and immunodiffusion (ID) 
wiih immunoblotting (IB) and VA RNA 
precipitation for the detection of anti-La 
antibodies. 
CIE negative sera 
CIE positive sera 
ID negative sera 
ID positive sera 
η 
109 
23 
11 
12 
IB 
positive 
η (%) 
1 ( 1) 
23 (100) 
η.t. 
n.t. 
VARNA 
positive 
η ( » ) 
22 (20) 
23 (100) 
5 (46) 
12 (100) 
n = number of patient sera 
n.t, = not tested 
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diagnosis 
ss 
-ргіпшіу 
-secondary 
SLE 
RA 
UCTD 
controls 
η 
46 
20 
26 
95 
IOS 
44 
11 
сшлв 
positive 
% 
48 
n.t. 
n.L 
13 
8 
21 
0 
VARNA 
positive 
* 
58 
85 
35 
35 
16 
36 
0 
other techniques. All of these 
TabUn: Percentage of ünti-La positive patient sera.
 χ τ Λ
 ρ ^ ρ ^ ^ Ц,«; charac­
teristic La RNAs like pre-5S, 
pre-tRNA and 7S RNA (data 
not shown), indicating that 
precipitation of VA RNA in 
adenovirus infected HeLa cell 
extracts is caused by the 
presence of anti-La antibodies 
in a serum and not by any 
other serum specificity. To 
. , . compare the sensitivity of 
η = number of patient sen r J 
n.t. = not tested immunodiffusion with VA 
RNA precipitation, a relatively 
small number of sera (n=23) 
was tested for anti-La activity. 
Twelve sera were found positive for anti-La (SS-B) by immunodiffusion and 5 more by 
VA RNA precipitation (Table I). 
To substantiate the use of VA RNA precipitation for the characterization of sera shown to 
be positive only for anti-Ro antibodies in СІБ, we tested 19 of such "Ro monospecific" 
sera by immunoblotting and VA RNA precipitation. Eleven of these 19 sera were found 
positive for anti-La antibodies by the VA RNA method, but were negative by 
immunoblotting as well as by СШ (Table I). All 19 sera were positive for anti-Ro 
antibodies as indicated by the precipitation of Ro RNAs. This result not only corroborates 
the extreme sensitivity of the VA RNA precipitation method for the detection of anti-La 
antibodies but underlines also the reliability of the method for the demonstration of anti-
Ro antibodies. 
The presence of anti-La antibodies in CID patients 
It is known that anti-Ro and anti-La antibodies occur predominantly in sera from 
patients with SLE and/or Sjogren's syndrome (SS). To investigate whether the presence 
of low levels of anti-La antibodies is related to one of these disorders, we classified the 
sera tested by VA RNA precipitation, CŒ and immunoblotting according to diagnosis. As 
can be concluded from Table П, the presence of previously undetected low-titer anti-La 
antibody levels enhances the number of anti-La positive sera in every group of patients, 
but especially in SLE patients. When SS sera are divided in their respective serological 
subgroups, anti-La antibodies are most frequently found in sera from primary SS patients 
(85%). 
Discussion 
In this paper we show that after adenovirus infection of HeLa cells the synthesis 
of most small RNAs is stopped. An exception is the synthesis of the Ro RNAs that 
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proceeds at seemingly normal rates. The Ro RNAs still associate with the Ro antigen 
while the La antigen becomes predominantly associated with virally encoded VA RNA 
transcripts. A selective labeling procedure was then developed to allow the simultaneous 
and sensitive detection of anti-Ro and anti-La autoantibodies. 
To detect the presence of autoantibodies in sera from patients suffering from 
connective tissue diseases many methods are routinely employed. Immunodiffusion and 
counter immunoelectrophoresis are highly specific but relatively insensitive since 
precipitating antibodies can only be demonstrated at an optimal antigen/antibody ratio. 
Furthermore, immunodiffusion and CIE are sometimes difficult to interpret when sera are 
used that contain multiple specificities (Williams et a., 1986). Immunoblotting is probably 
the most sensitive technique used routinely at the moment, but the method is not so easy 
to perform and has the possible disadvantage of not demonstrating antibodies that 
recognize conformational epitopes. Immunoprecipitation is an even more sensitive 
technique, highly specific but very time consuming. However, when it is essential to 
know whether anti-Ro and anti-La antibodies are present, a precipitation assay should be 
used that gives an unambiguous answer, i.e. precipitates a well defined complex, as for 
example the VA RNA-La protein complex. 
The precipitation assay described here is more sensitive for the detection of anti-
La antibodies than all other methods described previously due to the large amount of VA 
RNA synthesized in adenovirus-infected HeLa cells, its specific interaction with the 
cellular La protein and the high specific activity that can be obtained by [32P]-labelling of 
adenovirus-infected HeLa cells. A further advantage of the method is that anti-Ro 
antibodies, often present in anti-La sera, can be detected simultaneously by the 
precipitation of the Ro RNAs hYl-hYS when the infected and labeled cells are chased 
with non-radioactive medium. Although the La protein is also capable of binding to the 
Ro RNAs, the majority of the Ro RNAs are specifically precipitated by the anti-Ro and 
not by the anti-La antibody. The explanation for such a behaviour may be that the La 
protein only transiently associates with the Ro RNAs (Hendrick et al, 1981, and figure 
1С, lanes 1-3), so that these RNAs will not be present in a La precipitation pattern when 
a chased cell extract is used. 
Our results clearly show the sensitivity of the VA RNA precipitation method for 
the demonstration of low concentrations of anti-La antibodies in patient sera. Compared to 
counter immunoelectrophoresis, 22 out of 109 CIE negative sera precipitated VA RNA 
while only 1 was found positive for anti-La antibodies by immunoblotting (Table 1). All 
of the sera found to be positive by CIE and immunoblotting for anti-Ro and anti-La 
antibodies were also positive for both activities in the VA RNA precipitation assay. 
When differentiated according to diagnosis, anti-La antibodies were found at a 
higher incidence in all classes of connective tissue disease patients then hitherto has been 
described. For RA (16%) and UCTD (36%) this increase seemed relatively insignificant, 
when compared with data from previous studies (Maddison et al., 1985; Harley et al, 
1986; De Rooij et al., 1988), but for SLE patients the incidence of anti-La antibodies is 
more strikingly influenced (35% positive as compared to 10-15% mentioned before (De 
Rooij et al., 1988; Chan et al., 1989). When Sjogren's syndrome patients are subdivided 
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in subclasses, anti-La antibodies are primarily found in primary SS (85%) and to a minor 
extent in secondary SS (35%). For both primary and secondary SS these figures agree 
well with those published in previous reports (AJrizuki et al., 1976; Kassan et al, 1977; 
Isenberg et al., 1982; Venables et al., 1983). However, it is clear that the higher 
sensitivity of detection almost automatically leads to a lowered specificity for anti-La 
antibody as a disease marker for SS and SLE (see Table Π). 
For studies on the complexity and function of Ro and La ribonucleoproteins 
monospecific sera are indispensable. Since good monoclonal antibodies directed against 
these complexes are relatively rare, monospecific human sera are a useful alternative. 
However, this study clearly shows that counter Immunoelectrophoresis, immunodiffusion 
and immunoblotting techniques are not sufficient to select such sera. In fact, monospecific 
anti-Ro and monospecific anti-La sera proved to be more rare than hitherto was expected. 
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Abstract 
The simultaneous detection of anti-La, anti-60 kDa Ro and anti-52 kDa Ro antibodies 
by immunoblotting is greatly improved by changing the crosslinking level in the gel to an 
acrylamide/bisacrylamide ratio of 19:1. Using this method for the analysis of a number of 
SLE and Sjogren's syndrome patient sera it was observed that antibody to the 52 kDa Ro 
protein without anti-60 kDa Ro antibody was restricted to Sjögren 's syndrome patients (9/26), 
whereas antibody to the 60 kDa Ro protein without contaminating anti-52 kDa Ro antibody 
was only found in SLE patients (4/38). Moreover, in Sjögren 's syndrome patient sera anti-Ro 
antibody was found only in combination with anti-La antibody (20/26), whereas in SLE 
patient sera anti-Ro antibody could be found without detectable anti-La specificity (8/38). 
Double immunofluorescence microscopy revealed that the 52 kDa Ro and the 60 kDa Ro 
proteins co-localize in the cytoplasm as well as in the nucleus, whereas immunoprecipitation 
off2P]-labelled HeLa cell extract with monospecific anti-52 kDa Ro and anti-60 kDa Ro sera 
showed that both proteins are associated with the Ro RNAs. These data suggest the presence 
of both the 52 kDa and the 60 kDa Ro proteins in the same ribonucleoprotein complexes. To 
study the evolutionary conservation of the 52 kDa Ro, the 60 kDa Ro and the La proteins, 
extracts of cell lines derived from various mammalian species were analysed on Western blots 
using monospecific human antibodies. In contrast to the 60 kDa Ro and the La antigens 
which are well conserved in evolution, the 52 kDa Ro antigen could be detected in primate 
ceto only by this immunological approach. The implications of the selective reactivity of anti-
52 kDa Ro antibodies with primate 52 kDa Ro antigen is discussed. 
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Introduction 
In patients with autoimmune disorders protein antigens, often associated with RNA 
in ribonucleoprotein (RNP) complexes, become targets of the immune system leading to the 
occurrence of autoantibodies. In systemic lupus erythematosus (SLE) and Sjogren's syndrome 
(SS) these autoantigenic targets include the Ro (SS-Α) and La (SS-B) RNP complexes. Many 
studies have pointed to the diagnostic value of antibodies to the Ro and La antigens, as these 
have frequencies of 60% and 40% respectively in SS and 35% and 15% respectively in SLE 
patient sera (reviewed by Chan and Tan, 1989a). 
The La RNP, predominantly localized in the cell nucleus, consists of a 46.7 kDa 
antigenic protein which binds non-covalently to RNA polymerase ΙΠ transcribed RNAs (e.g. 
pre-5S, pre-tRNAs and Ro RNAs). The La protein binds to the uridine stretch at the 3' end 
of the transcripts and functions as an RNA polymerase ΙΠ transcription termination factor 
(reviewed by Pruijn et al., 1990). 
In human cells, the Ro RNP complexes consist of four RNAs, termed hYl)hY3,hY4 
and hY5, each complexed to a single 60 kDa antigenic protein (Ro60). Complementary 
DNAs encoding the Ro60 protein have been cloned (Deutscher et al., 1988; Ben-Chetrit et 
al., 1989). Recombinant Ro60 was shown to be antigenic and could be reconstituted in vitro 
with hYl RNA. Recently, another putative component of the Ro RNPs, the 52 kDa Ro 
protein (Ro52), was identified (Ben-Chetrit et al., 1988). Apart from Ro60 and Ro52 three 
more proteins have been designated Ro proteins. Two of these, with molecular weigths of 
60 kDa and 54 kDa, were found in erythrocytes only and thus might be tissue specific Ro 
components (Rader et al., 1989a). Both of these proteins were antigenically distinct from the 
Ro60 and Ro52 polypeptides discussed above, but the 60 kDa proteins from red blood cells 
and lymphocytes as well as the 54 and 52 kDa proteins from these cells were shown to be 
related. Another putative Ro protein, the human analogue of calreticulin (McCauliffe et al., 
1990) has been cloned recently but its behaviour as a Ro component is as yet not clear. 
The evolutionary conservation of the Ro and La proteins has been the subject of 
several studies. Originally, the Ro antigen was described in human and mouse cells 
(Hendrick et al., 1981). Later, Harmon et al. (1984) described the absence of Ro antigen in 
mouse, rat, rabbit, hamster and chicken cells and the presence of Ro complexes in human, 
monkey, dog and guinea pig cells, whereas Mamula et al. (1989) could demonstrate Ro 
RNPs in human, bovine, rabbit and duck cells. Recently, the red blood cell and lymphocyte 
Ro antigens have been described in human, baboon, guinea pig, dog, bovine and mouse cells 
(Byers et al., 1990), although in this study an antiserum with mixed Ro60, Ro52 and La 
specificities was used, which seriously hampers the interpretation of the Western blots. 
In this study a gel system was designed to separate Ro60, Ro52 and La in order to 
detect anti-Ro and anti-La antibodies in patient sera on Western blots. RNA precipitation and 
immunofluorescence was performed to confirm the co-existence of Ro60 and Ro52 in the 
same RNP complexes and finally a panel of cell lines from different mammalian species was 
analyzed in order to study the evolutionary conservation of the Ro and La antigens. 
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Materials and methods 
Cell extracts and immunobloning 
Cytoplasmic extract of Raji cells was prepared as described before (Ben-Chetrit et al., 
1988) and used for routine immunoblotting (2.5 mg protein per gel; dimensions 
150xl50xl.5mm) as described by Habets et al. (1985), using 10% SDS-PAGE gels 
(Laemmli, 1970) with modified acrylamide to bisacrylamide ratios as indicated in the legend 
of Figure 1. Strips of these blots were blocked with PT-buffer (PBS-0.5% Tween20) 
containing 3% bovine serum albumin (BSA) for 30 min and incubated with antiserum in PT-
1% BSA, diluted 1/100, for 2h. After 3 washes with PT, the strips were incubated with 
[125I]-protein A (Amersham, UK) in PT with 1% BSA (1 /xCi per 100 ml) for 2h. After 
extensive washing with PT (3x) and water (3x) the strips were autoradiographed for various 
periods using Kodak XAR5 films. 
To establish the monospecificity of the antisera, Western blots were prepared 
containing bacterially expressed Ro60 and La proteins (unpublished results) and incubated 
as described before (Habets et al., 1985). 
HeLa cells were labelled overnight at a density of 0.5 χ IO6 cells/ml with [32P]-
orthophosphate (0.5 mCi/ml). Cytoplasmic extracts were prepared as described above and 
used for immunoprecipitation as described by Slobbe et al. (1991). 
Western blots of cell extracts originating from cell lines of different species were 
obtained as follows: Approximately 40Ί06cells were harvested and washed once with PBS 
pH7.0. After resuspending the cells in 500 μ\ RSB110 (lOmM Tris-HCl pH7.4, 1 lOmM NaCl, 
1.5mM MgClî containing 0.5mM Phenylmethylsulfonyl chloride [PMSC]), cells were lysed 
by repeated freeze-thawing. After lysis cell extracts were incubated with 250 /ig DNAse I 
and, after removing cell debris by centrifugation, the protein content was determined using 
the method of Lowry et al. (1951) using BSA (Sigma, USA) as a standard. About SOjig of 
protein was loaded per lane of the SDS-PAGE gel and blotted as described above. 
Anrisera 
All patients were diagnosed according to established criteria (de Rooij et al., 1988): 
All patients with SLE were positive on 4 or more of the revised criteria of the Amerian 
Rheumatism Association (Tan et al., 1982) and all SS patients were positive for 
xerophtalmia, xerostomia and/or salivary gland infiltration (Alexander et al., 1982). 
For the detection of antigens on Western blots several patient sera were used: O60 
and 012 (containing anti-Ro60, anti-Ro52 and anti-La antibody), H142 (containing only anti-
Ro60 antibody), Jo7 (containing only anti-Ro52 antibody), W10 (containing anti-La and anti-
Ro52 antibody) and reference serum Ge (courtesy of Prof. E.M. Tan, containing antibodies 
to both Ro60 and Ro52). In addition, a polyclonal rabbit anti-Ro60 antiserum, prepared by 
immunizing a rabbit with recombinant Ro60 protein (unpublished results), was used for the 
double immunofluorescence microscopy. Antibodies to Ro60 and La peptides were affinity 
purified using bacterially expressed antigens coupled to CNBr-activated Sepharose 4B 
(Pharmacia, Sweden) according to protocols supplied by the manufacturer. 
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Immunofluorescence microscopy 
Double immunofluorescence microscopy using a human monospecific anti-Ro52 serum 
and a monospecific polyclonal rabbit anti-Ro60 serum was performed on human HEp-2 cells. 
First, the cells were fixed with methanol for 5 minutes (-20oC), rinsed with acetone (-20oC) 
and air dried. The fixed cells were incubated with the monospecific human anti-Ro52 serum 
(diluted 1/50 with PBS) for 30 min followed by incubation with FITC labelled goat anti-
human second antibody for 30 min. Subsequently, the incubated cells were stained with the 
affinity purified rabbit anti-Ro60 polyclonal antiserum (diluted 1/50 with PBS) for 30 min, 
followed by incubation with TRTTC labeled swine anti-rabbit second antibody for 30 min. 
Second antibodies (Dakopatts, Denmark) were used at a dilution of 1/50 in PBS. All possible 
combinations of antibody control incubations were included and found to be negative. 
Results 
Separation ofRoóO, Ro52 and La polypeptides in SDS-PAGE 
Since the discovery of the 52 Ша Ro protein as a major Ro autoantigen, several gel 
systems have been used to detect Ro52 on immunoblots. Using a Ro52 reference serum 
containing antibodies to both Ro60 and Ro52 but not to the La protein we were able to detect 
Ro52 in our usual gel system, migrating at the same position as the La protein (Figure 1, 
lanes 5 and 7, middle panel). Since anti-La and anti-Ro antibodies frequently concur in 
patient sera, an alteration in the antigen separation was required for the detection of both 
anti-Ro and anti-La autoantibodies in patient sera by this method. Changing the crosslinking 
percentage in the gel by varying the ratio of acrylamide to bisacrylamide from 39:1 to either 
79:1 (left panel) or 19:1 (right panel) revealed that, while La and Ro60 do not change 
migration relative to each other, the relative position of Ro52 is markedly affected. At a ratio 
of 79:1, Ro52 migrates slower than the La protein (Figure 1, left panel, lanes 4,5 and 7), 
1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 
79:1 39:1 19:1 
Fig.l. Western blots of SDS-PAGE gek with different acrylamide to bisacrylamide ratios 
In the left panel an acrylamide to bisacrylamide ratio of 79:1 was used, in the middle a ratio of 39:1 and on the 
right 19:1. Lanes 1: normal human serum; lanes 2 and 3: sera with anti-Ro60, anti-Ro52 and anti-La antibodies 
(O60 and 012 respectively); lanes 4: anti Ro52 antiserum (JoT); lanes 5: reference serum Ge (anti-Ro60 and anti-
Ro53; lanes 6: anti-Ro60 antiserum (H142); lanes 7: serum containing anti-La and anti-RoS2 antibodies (W10). 
The positions of the Ro60, Ro52 and La proteins on the blots are indicated by D, О and · respectively. 
Background band typically present in Raji cell extracts is marked by an asterisk. 
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panel A: The occurrence of anli-Ro and anti-La antibodies in sera from patients with Sjogren's syndrome, panel 
B: The presence of anti-Ro and anti-La antibodies in sera from patients with systemic lupus erythematosus. 
Numbers in the figure indicate the number of positive patient sera. The patterns are as indicated. 
at a ratio of 39:1 it comigrates with the La protein, while at a ratio of 19:1 Ro52 migrates 
faster than La (Figure 1, right panel, lanes 4,5 and 7). The separation of Ro52 from La and 
Ro60 is best in the latter gel system, enabling the detection of antibodies to all three proteins 
simultaneously (Figure 1, lanes 2, 3 and 6; compare left and right panel). Consequently, this 
system was used in the experiments described below. 
Detection ofarui-Ro60, anti-Ro52 and anti-La antibodies in autoimmune patient sera 
Using the immunoblotting system described above, a number of patient sera were 
analysed for the presence of anti-Ro60, anti-Ro52 and anti-La antibodies. As summarized in 
Figure 2, sera from patients with SLE and Sjogren's syndrome often contain antibodies to 
the Ro and La antigenic proteins. However, anti-Ro52 antibody without anti-Ro60 antibody 
was found only in sera from patients with Sjogren's syndrome (9/26; 34%), whereas anti-
Ro60 antibody without concomitant anti-Ro52 antibody was demonstrated only in SLE sera 
(4/38; 10%). Moreover, anti-Ro antibody without anti-La antibody was detected in SLE 
patients only (8/38; 21%), whereas in all anti-Ro positive sera from patients with Sjogren's 
syndrome anti-La antibody was detected as well (20/26; 77%). Sera from healthy controls 
did not contain detectable levels of anti-Ro60, anti-Ro52 or anti-La antibodies. 
Characterization of monospecific antisera 
To obtain antibodies monospecific for either the Ro60 or the La antigen, specific 
antibodies were immunoaffinity purified using recombinant antigen coupled to CNBr-
activated Sepharose 4B yielding monospecific anti-La and anti-Ro60 antibodies from patients 
and monospecific rabbit anti-Ro60 antibody. For anti-Ro52 antibody a serum was used that 
did not contain detectable levels of anti-Ro60 or anti-La antibody on immunoblot. To remove 
possible trace amounts of anti-Ro60 antibody, this serum was passed repeatedly over a Ro60-
column, that had been shown to be able to remove anti-Ro60 antibodies from an anti-
Ro60/La serum. 
The resulting monospecific sera were checked for their monospecificity in various 
ways: first, Western blot analysis of these monospecific sera did not show the presence of 
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Fig.3. Evidence for the monospecificity cfihe anti-ЯобО, aiai-RoS2 and anti-La antibody. 
panel A; Western blot of HeLa cytoplasmic extract incubated with monospecific anti-Ro60 (lane 2), anti-Ro52 
(lane 3) or anti-La (lane 4) scrum. Lane 5 contains a reference serum with antibodies to Ro52, R06O and La 
(O60), lane 1 normal human serum. Degradation products of La are indicated by asterisks, panel B: Western blots 
of recombinant R06O (left) and recombinant La (light) protein. In lane 1 total protein is stained with Ponceau S 
(Sigma Diagnostics, USA), in lanes 2 normal human serum, in lanes 3 rabbit anti-Ro60 antibody, in lanes 4 
human affinity purified anti-Ro60 antibody, in lanes 5 human afFmity purified anti-La antibody, in lanes 6 human 
monospecific anti-Ro52 antibody, in lanes 7 anti-Ro (SS-Α) and in lanes 8 anti-La (SS-B) antiscra were used 
(CDC, Atlanta, USA). 
any contaminating antibody (Figure 3, panel A); second, using Western blots containing large 
amounts of bacterially expressed recombinant R06O or La polypeptides revealed that only the 
monospecific anti-Ro60 and the monospecific anti-La reacted with the respective antigens 
(Figure 3, panel B); third, the absence of low levels of anti-La antibody in the anti-Ro sera 
was tested by the immunoprecipitation of VA RNA from adenovirus infected cell extracts 
(Slobbe et al., 1991) and none of the purified anti-Ro antibodies precipitated VA RNA 
(results not shown). 
RNA precipitation and double immunofluorescence microscopy using monospecific anti-Ro52 
and anti-Ro60 antisera 
RNA precipitation from ["Pj-labelled HeLa cell extract with monospecific anti-Ro52 
and monospecific anti-Ro60 antibody showed that both anti-Ro52 and anti-Ro60 antibody 
precipitated the characteristic Ro RNAs (Figure 4, panel A, lanes S and 6). As controls RNA 
precipitations performed with normal human serum (lane 2), anti-Ro (SS-A) CDC reference 
serum (lane 3), affinity purified rabbit anti-Ro60 antibody (lane 4), anti-La CDC reference 
serum (lane 7) and affinity purified anti-La serum (lane 8) are included. 
We used indirect immunofluorescence to determine the intracellular localization of the 
R06O and RoS2 proteins at a light microscopic level. Antibodies to either the R06O or the 
RoS2 protein yielded a diffuse cytoplasmic staining next to a strong punctuated nuclear 
staining, while the nucleoli were negative. Double immunofluorescence using monospecific 
rabbit polyclonal anti-Ro60 antibodies and monospecific anti-Ro52 patient antibodies showed 
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Fig. 4. Evidence for the association ofRo60 and Ro52 in Ro RNP complexes. 
panel A: RNA precipitation of HeLa [,2P]-labelled cellular extract immunoprecipitated with normal human serum 
(lane 2), anti-Ro (SS-Α) reference serum (CDC, Atlanta, USA; lane 3), monospecific polyclonal rabbit anti-Ro60 
antibody (lane 4), affinity purified monospecific human anti-Ro60 antibody (lane 5), monospecific anti Ro52 
antiserum (lane 6), anti-La (SS-B) reference serum (CDC, Atlanta, USA; lane 7) and affinity purified 
monospecific anti-La antibody (lane 8). In lane 1 total ["PJ-labcllcti RNA is shown, panel B; Double 
immunofluorescence microscopy of HEp-2 cells incubated with rabbit anti-Ro60 antibody and human anti Ro52 
antiserum. In panel I, TR1TC labelled anti-rabbit antibody (anti-Ro60), in panel II FITC labelled anti-human 
antibody (anti-Ro52) is shown. Magnification XOOx. 
that both staining patterns were identical, suggesting the co-localization of both proteins (see 
Figure 4, panel B). 
Detection ofRoóO, Ro52 and the La protein in extracts of tissue culture cells originating from 
different species 
To study the evolutionary conservation of R06O, Ro52 and the La protein, a panel of 
mammalian cell line extracts was immunoblotted with the monospecific sera described above. 
As shown in Figure 5, R06O and the La protein are well conserved in evolution as 
indicated by the apparent conservation of epitopes, although reactivity of the antigens and 
their apparent molecular weights seem to differ among species. Despite the use of PMSC as 
protease inhibitor, some proteolytic degradation was observed, especially of the La protein, 
which is very susceptible to proteolytic degradation (Habets et al., 1983; Chanetal., 1989b). 
This resulted in La-degradation products of 43 and 28 kDa molecular weight (marked by an 
asterisk in Figure 5). In Vero cell extracts the apparently high protease activity has caused 
degradation of La and some degradation of R06O as well. In contrast to the conservation of 
R06O and the La polypeptide, Ro52 could be detected only in cell lines originating from 
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primates, which indicates that either the antigenic determinants of Ro52 have altered during 
evolution or that a protein related to Ro52 is absent in mammals other than primates. An 
extract of chimpanzee liver tissue also contained all three proteins (results not shown). 
Discussion 
The use of a modified gel system to detect unambiguously the Ro52 antigen on 
Western blots is described. While this work was in progress, other investigators reported 
similar observations (Buyon et al., 1990) and suggested conformational effects in the presence 
of SDS causing the aberrant migration of the 52 kDa Ro protein on Laemmli gels. Structural 
studies of Ro52 have to be awaited to gain insight into the phenomena causing this deviant 
behaviour. 
Using our modified gel system for the detection of anü-Ro (SS-Α) and anti-La (SS-B) 
autoantibodies in patient sera we established that anti-Ro52 and anti-Ro60 antibodies are often 
found in patients with SLE or Sjogren's syndrome (SS) (15/38 for SLE and 20/26 for SS 
patients). Our results confirm recent data from Ben-Chetrit et al. (1990) that sera containing 
anti-Ro52 but not anti-Ro60 antibodies seem to be restricted to SS patients, whereas anti-
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Ro60 without anti-RoS2 antibodies could only be found in SLE patients (see Figure 2). 
Additionally, in all sera from patients with Sjogren's syndrome containing anti-Ro antibody, 
anti-La antibody could be detected as well. In contrast, anti-Ro antisera without anti-La 
antibody were found only in the SLE patient group. This latter finding confirms results of 
previous reports (Wasicek and Reichlin, 1982; Rader et al., 1989b). Therefore, based upon 
these results, it is likely that the presence of anti-Ro60 antibody without anti-La antibody in 
autoimmune patient sera is indicative for SLE, whereas the presence of antì-Ro52 and anti-La 
antibody without anti-Ro60 antibody is restricted to sera from patients with Sjogren's 
syndrome. 
To confirm the association of Ro52 with Ro RNP complexes, RNA precipitations with 
monospecific anti-RoS2 or anü-RoóO antibody were carried out. The results showed that 
monospecific antibodies to both antigens were able to precipitate the characteristic Ro RNAs. 
Since the Ro RNA precipitation patterns do not seem to differ in Ro60 and Ro52 
precipitation it is concluded that both Ro60 and Ro52 are associated with all four Ro RNAs. 
This renders it unlikely that differences observed in Ro RNP particles (Boire and Craft, 
1990) are caused by differential binding of Ro52 or Ro60 to the Ro RNAs. Moreover, double 
immunofluorescence microscopy showed that the RoS2 and Ro60 antigens co-localize in the 
nucleus as well as in the cytoplasm, indicating an intimate relation between these proteins. 
The evolutionary conservation of Ro60, Ro52 and the La protein was studied by 
incubating Western blots of cell extracts from cell lines originating from different species 
with monospecific polyclonal antisera. This method may have the disadvantage of not 
demonstrating antigens whose antigenic determinants have altered during evolution, but the 
polyclonality of the patient sera used still allows the detection of proteins containing only a 
limited number of conserved epitopes. The Western blots shown in Figure 5 reveal that the 
antigenic properties of Ro60 and La seem to be well conserved during evolution, since 
proteins of comparable molecular weight are recognized by the antisera in each cell line 
tested. In the case of the La protein it is noteworthy that degradation products of 
approximately 43 and 28 kDa, previously identified in human cell extracts (Habets et al., 
1983; Chan et al., 1989b) are also found in other species, indicating the conservation of 
regions in the protein that are susceptible to protease digestion. The apparent molecular 
weights of both Ro60 and La seem to differ slightly among species, possibly caused by 
structural differences or by proteolytic degradation. Additionally, the intensity of reacting 
antigen seems to vary among species. This may be due to variations in abundance of the 
antigens and/or antibody reactivity. Some variation in the levels of reacting antigen may be 
caused by tissue specific expression of the antigenic proteins. It has been reported that 
isoforms of the Ro proteins with different antigenicity exist in human red blood cells as 
compared to lymphocytes (Rader et al, 1989a). Therefore, it cannot be excluded that the 
antibody used in this study has a different affinity for some tissue specific isoforms of Ro. 
For example, it is known that rabbit thymus extracts contain little or no Ro (SS-Α) complexes 
detectable with human antisera (Reichlin and Reichlin, 1989), whereas we find a weak 
reactivity with anti-Ro60 antibodies in rabbit kidney cells (Figure 4). 
Interestingly, the RoS2 protein could only be demonstrated unambiguously in human and 
monkey cell lines. Whether the lack of reactivity of the anti-RoS2 antibody in mammalian 
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cells other than primate cells reflects the absence of a related protein is not entirely clear. 
Although these experiments could be reproduced several times and the same result was 
obtained using three different patient sera, it still seems possible that only major epitopes of 
Ro52 have altered during evolution and that a related, but antigenically distinct, protein is 
present in other mammalian species. The availability of DNA probes for screening different 
species for the expression of this antigen on Northern blots might answer this question. Still, 
the reactivity of patient antibodies with primate Ro52 only is rather unexpected since most 
autoantibodies have been reported to react with antigens of different species. For instance, 
reactivity of autoantibodies to the Sm antigen has been found in a broad range of vertebrates 
and in Drosophila (Mount et al., 1981), autoantibodies to the Jo-1 antigen (histidyl-tRNA 
synthetase) react with human, bovine, rat and rabbit protein (Nishikai et al., 1980, Mathews 
and Bernstein, 1983, Yang et al., 1984), anti-nucleolar 34 kDa fibriUarin antibodies recognize 
the human, mouse and Drosophila nucleoli (Lischwe et al., 1985), and anti-La antibodies are 
known to be reactive with proteins of comparable molecular weights in a number of 
mammalian species (this study) and with Xenopus laevis La antigen (Moreau et al., 1990). 
Species-specific recognition of an autoantigen has been reported only for the antì-Ku 
autoantibody (Mimori et al., 1981), that does react with human and bovine tissue but not 
with mouse liver. If Ro52 indeed is a primate specific autoantigen, then it would support the 
idea that the human autoantigen itself functions as a trigger in the onset and perpetuation of 
the immuneresponse. 
Finally, since RoS2 could not be detected in mammals other than primates and anti-Ro 
(SS-A) sera frequently contain antibodies to this protein, it is evident that one should be 
careful in choosing cell extracts for performing counter-immunoelectrophoresis, ELISA or 
Western blotting for the screening of patient sera. 
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Appendix: 
The evolutionary conservation of Ro RNAs 
R.L.Slobbe, P.A.E.T.M. Wingens, G.J.M. Pruijn and W.J. van Venrooij 
The results presented in Chapter 3 show that the 60 kDa Ro antigen is reasonably well 
conserved in evolution as indicated by the immunological reactivity of proteins of similar size 
in mammalian cells other than human cells. The 52 kDa protein, however, could be detected 
immunologically in primate cells only. This suggests that either the autoepitopes of the 52 
kDa Ro protein have altered in evolution and that a similar, but immunologically non-
reactive, protein is present in non-primate cells or that a protein related to Ro52 is absent in 
non-primates. 
Because of this difference in evolutionary conservation between the 60 kDa and 52 
kDa Ro antigens and the fact that they are both present in the same ribonucleoprotein 
complex in human cells, we analyzed the evolutionary conservation of Ro RNAs in 
mammalian cells as well. Previous studies have identified Ro RNAs in human, bovine, cavia, 
leporine, rat, murine and duck cells via immunoprecipitation of Ro RNP complexes 
(Hendrick et al., 1981; Reddy et al., 1983; Itoh et al., 1990; Mamula et al., 1990). In these 
studies the number of Ro RNAs varied between two (in murine and duck cells) and four (in 
human, bovine and guinea pig cells), but the identity of the RNAs of these species was not 
elucidated. The only report on the identity of Ro RNAs in other species shows that in murine 
cells two Ro RNAs exist (referred to as mYl and mY2), that are homologous to hYl and 
hY3, respectively (Wolin and Steitz, 1983). 
Total RNA was isolated from cells of different mammalian species by two subsequent 
phenol extraction procedures (Sambrook et al., 1989). The isolated RNAs were separated by 
polyacrylamide-urea gel electrophoresis, electroblotted onto Hybond N membrane and 
subsequently hybridized with antisense hYl, hY3 and hY5 RNA probes to detect the presence 
of RNAs homologous to hYl, hY3 or hY5, respectively. 
As shown in Figure Al and summarized in Table AI, both antisense hYl and 
antisense hY3 RNA probes hybridized with RNAs of similar size in RNA preparations of all 
mammalian species examined. This indicates that RNAs homologous to hYl and hY3 are 
present in all of these cells and that the Yl and Y3 RNAs are well conserved in evolution. 
It is noteworthy that upon hybridization with antisense hYl RNA often two strongly 
hybridizing bands were found, probably corresponding to hYl and a degradation product 
thereof, previously described as hY2 (Hendrick et al., 1981; Wolin and Steitz, 1983). In 
spite of the stringent conditions used during hybridization both antisense hYl and hY3 probes 
hybridized to the other Y RNAs, albeit at a significantly lower level. 
Antisense hY5 RNA hybridized very specifically with RNA of similar size in all 
examined RNA preparations of mammalian species, except for cow, mouse, rat and hamster 
RNA. These results suggest that Y5 RNA is not universally present. 
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Fig.Al. The evolutionary conservation of Y RNAs 
Total cellular RNAs were isolated from cells originating 
from different mammalian species as indicated on top 
of the Figure, separated on a 10% Polyacrylamide-urea 
Probe ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ и 8 e l a n <i electroblotted onto a Hybond N membrane. 
This Northern blot was subsequently hybridized with 
equal amounts of anti-sense hYl, hY3 and hY5 RNA 
probes of identical specific activity (conditions: 6xSSC, 
68 °C), as indicated on the left. 
Table AI The presence of Y RNAs in different 
mammalian species 
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hY5 ' e v ' ( l c n c e for tf·6 presence of Y4 homologues is 
derived from the presence of an RNA of similar length 
as h Y4 RNA, cross-hybridizing with the antisense hYl 
RNA probe and not hybridizing with the anti-sense hY3 
and hY5 probes as determined by superimposing the 
autoradiograms. 
conclusion concerning the presence of hY4 homologues can be drawn from these blots. 
However, since the antisense hYl RNA probe cross-hybridized with all four Ro RNAs in 
human cells (including hY4 RNA), it is tempting to presume that the presence of bands 
cross-hybridizing with the hYl RNA probe, but not hybridizing with the anti-sense hY3 or 
hY5 probes (as determined by superimposing the autoradiograms) and of similar length as 
hY4, are indicative for the presence of Y4 RNA. If these assumptions are allowed, then it 
seems that a Y4 RNA homologue is present in all mammalian species but mouse, rat and 
hamster. 
Cellular extracts of Xenopus laevis, moth, bean, tomato, potato, tobacco and 
Saccharomyces cerevisiae were also analyzed for the presence of Ro RNAs. Yl, Y3 and Y5 
RNAs could not be detected in these species under stringent hybridization conditions, 
indicating that Y RNAs are probably not present. 
Generally, the data presented here are in agreement with previous reports, although 
some deviations were found. In rabbit cells, an RNA homologous to but migrating slightly 
faster than hY5 was detected, whereas others described the presence of only three larger 
RNAs, approximately of the size of hYl, hY3 and hY4. Additionally, four Ro RNAs have 
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been described in bovine cells, whereas in Figure Al only three Ro RNAs, homologous to 
hYl, hY3 and (probably) hY4 could be identified. An explanation for these deviating results 
may be the fact that in other studies anti-Ro immunoprecipitated RNA was analyzed, whereas 
here total RNA has been examined. Another cause might be possible degradation of Y 
RNAs; for example, Yl RNA may be degraded to Y2 RNA. 
The possibility that the analysis of total RNA may differ from the analysis of anti-Ro 
immunoprecipitated RNA is supported by another observation. The analysis of the presence 
of Ro RNAs in total RNA preparations can be interpreted quantitatively, since the blot in 
Figure Al is incubated with equal amounts of anti-sense RNA probes of similar specific 
activity. In addition, hybridization of this blot with a mixture of equal amounts of anti-sense 
hYl, hY3 and hY5 RNA probes of similar specific activities yielded identical results (results 
not shown). As a result, it seems that Yl and Y5 RNAs are present in equal amounts in 
mammalian cells, whereas Y3 RNA is less prominent. This seems to conflict with the data 
presented in Chapter 4, Figure 4A. In RNA preparations obtained by immunoprecipitation 
of [32P]-orthophosphate labelled HeLa cell-extracts with anti-Ro antisera, hY5 RNA from 
appears to be much more abundant than hYl and hY3 RNA. Therefore, since hYl RNA is 
relatively more abundant in total RNA preparations than in anti-Ro immunoprecipitated RNA, 
it might be possible that part of the hYl RNA molecules are not complexed with the Ro 
antigens. 
Taken together, parts of the Ro RNP complexes seem to be well conserved in 
mammals, i.e. R06O and La antigens and Yl and Y3 RNAs, whereas the Ro52 antigen and 
Y4 and YS RNA seem to be present in only a subset of mammals. The implications of this 
limited conservation of (parts of) the Ro RNP complexes for the function of the particles are 
not clear yet. In this respect, it is possible that some Ro RNPs (including Yl and Y3 RNA, 
support important functions in all mammals, whereas other Ro RNP complexes (containing 
Y4 and Y5 RNA) may be involved in species specific functions. 
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Abstract 
The interactions between Ro and La proteins and hY RNAs have been analysed. 
The binding site for the 60 kDa Ro protein on hY RNAs is shown to be the terminal part 
of the base paired stem structure, which contains the most highly conserved sequence 
among hY RNAs. The bulged C-residue within this region of hY RNAs plays an important 
role in the recognition by this protein. The same regions of hY RNAs are essential for the 
association of the 52 kDa Ro protein with the RNAs, strongly suggesting that the 60 kDa 
Ro protein is required for the 52 kDa Ro protein to bind, presumably via protein-protein 
interactions, to Ro RNPs. The binding site for the La protein on hY RNAs is shown to be 
the oligouridylate stretch near the З'-end of the RNAs, which is also recognized when a 
few additional nucleotides flank this motif at the З'-side. Additional sequence elements in 
hY3 and hY5, but not in hYl, are bound by the La protein as well. Deletion mutagenesis 
showed that the RNP motif, previously identified in many ribonucleoprotein (RNP) 
proteins and in some cases shown to be almost sufficient for the interaction with RNA, of 
both the 60 kDa Ro and the La protein are not sufficient for the interaction with hY 
RNAs. Substantial parts of these proteins flanking the RNP motif are needed as well. 
These results suggest that parts of these proteins outside the RNP motif stabilize the 
correct conformation of tins motif for RNA binding. 
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Introduction 
Ro RNPs are composed of several proteins complexed with the RNA polymerase 
Ш transcribed Y RNAs. In human cells four different Y RNAs, called hYl, hY3, hY4 
and hY5, all about 100 nucleotides in length, have been identified while in other species 
two to four Y RNAs have been found, always one of them being of hYl-size (Hendrick et 
al., 1981; Wolin and Steitz, 1983; Mamula et al., 1989a; Pruijn et al., 1990). In most 
human cells at least three proteins are associated with hY RNAs: the 60 kDa Ro protein 
(Ro60), the 52 kDa Ro protein (Ro52) and the La protein (Hendrick et al., 1981; Wolin 
and Steitz, 1984; Ben-Chetrit et al., 1988). However, in human red blood cells 
immunoreactive Ro proteins of 60 kDa (distinct from Ro60) and 54 kDa have been 
detected (Rader et al., 1989). Using an anti-Ro antiserum a third human immunoreactive 
60 kDa protein has been purified from Wil-2 cells (Lieu et al., 1988). Proteins 
immunologically related to Ro60 and La have been found in several other mammalian 
species while Ro52 could only be detected in extracts from primate cells (Hoch et al., 
1984; Slobbe et al., 1991). 
Ro RNPs can be considered a subset of La RNPs. After termination of RNA 
polymerase ΠΙ transcription, a step which only occurs accurately and efficiently in the 
presence of the La protein, this protein is associated with the oligouridylate stretch at the 
3' terminus of the newly transcribed RNA (Stefano, 1984; Mathews and Francoeur, 1984; 
Gottlieb and Steitz, 1989a, 1989b). The interaction of the La protein with most RNA 
polymerase ΠΙ products is lost upon maturation of the 3' end of the RNA. However, 
mature Y RNAs still contain a complete La binding site and a stable association of La 
with these Ro RNPs has been demonstrated (Mamula et al., 1989b; Boire and Craft, 
1990). 
Antibodies against Ro (both Ro60 and Ro52) and La, which are often present in 
sera from autoimmune patients, especially those suffering from Sjogren's syndrome and 
systemic lupus erythematosus (SLE), have been very helpful for the identification and 
characterization of Ro and La RNPs (Tan, 1989). Since these sera often contain 
antibodies against two or even three of these Ro and La proteins and since Ro52 
comigrates with La in usual gel systems, a modification of the gel system is required for 
accurate characterization of autoimmune sera by Western blotting (Buyon et al., 1990; 
Slobbeetal., 1991). 
The sequences of hYl, hY3, hY4 and hY5 have been determined and their 
predicted secondary structures are characterized by base-pairing of the 5' and 3' termini 
(Kato et al., 1982; Wolin and Steitz, 1983; O'Brien and Harley, 1990). The terminal part 
of the base-paired stem contains the most conserved nucleotides and this region was 
shown to be protected, presumably by bound proteins, against RNase degradation (Wolin 
and Steitz, 1984). 
Complementary DNAs encoding Ro60, Ro52, La and the Wil-2 60 kDa protein 
have been isolated and analyzed. Two, except for the 3' end, almost identical cDNAs 
encoding Ro60 have been isolated and are characterized by the presence of an RNP motif 
and a putative zinc finger (Deutscher et al., 1988; Ben-Chetrit et al., 1989). An RNP 
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motif encoding region was also found in La (cDNA) (Chambers et al., 1988; Chan et al., 
1989) while two putative zinc fingers are present in Ro52 (cDNA) (Chan et al., 1991; 
Itoh et al., 1991). The Wil-2 60 Ша protein cDNA encodes an acidic, calcium binding 
protein that contains an endoplasmic reticulum retention sequence and that is homologous 
to murine calreticulin (McCauliffe et al., 1990). 
Biochemical fractionation of human Ro RNPs has shown that, within a cell, 
different Ro RNPs with distinctive physicochemical properties can be distinguished and 
that Ro RNPs consist of their constituent RNA plus more than one polypeptide (Boire and 
Craft, 1990). Indirect evidence indicates that one Ro60 polypeptide binds to one Y RNA 
(Wolin and Steitz, 1984). The results of Ouchterlony analyses, immunoprecipi-tations and 
immunofluorescence studies suggest that all three proteins, Ro60, RoS2 and La, can be 
associated simultaneously with a single Y RNA (Ben-Chetrit et al., 1988; Mamula et al., 
1989b; Slobbe et al., 1991). However, the apparent molecular weights of the fractionated 
Ro RNPs in gel filtration, 230-350 kDa, can not be explained by the presence of only one 
copy of these proteins in such a particle (Boire and Craft, 1990). 
In this paper we have analysed the interaction of Ro60, Ro52 and La with h Y 
RNAs in vitro. Our results confirm previous data and unambiguously show that Ro60 and 
La bind directly to their presumed binding sites on hY RNAs. Additionally, La is shown 
to be able to interact with other sequences of hY3 and hY5. The analyses of the binding 
of HeLa S100 proteins to hY RNAs further strongly suggest that Ro52 requires Ro60 for 
its association with hY RNAs. Evidence for a direct protein-protein interaction between 
Ro60 and Ro52 will be documented in a separate paper (Slobbe et al., submitted). Неге 
we also analysed the binding of in vitro expressed recombinant Ro60 and La as well as of 
deletion mutants of both proteins to hY RNA was analysed. The results suggest that the 
RNP motif of both Ro60 and La is not sufficient for specific RNA binding. Other 
sequence motifs may be involved and/or, especially in case of Ro60, a correct 
conformation of the RNA-binding domain may be critically dependent on other parts of 
the protein. 
Materials and Methods 
Cloning of hY RNAs 
pHYl and pHY3 were constructed as follows: Via PCR the coding sequences of 
the hYl RNA and hY3 RNA genes were isolated out of a human genomic fragment 
harbouring both genes (a kind gift of Dr J.A. Steitz) using the following primers: 
for hYl S'-CTGAATTCGGCTGGTCCGAAGGTAGTGA-S' and 
5'-CTAAGCTTAAAAGACTAGTCAAGTGCAGT-3' 
for hY3 S'-CTGAATTCGGCTGGTCCGAGTGCAGT-S· and 
S'-CTAAGCTTAAAAGGCTAGTCAAGTGAAGC-S'. 
A comparable fragment for hY5 was obtained by reverse transcription of a hY RNA 
enriched HeLa RNA preparation using a primer complementary to the З'-end of hYS (5'-
CTAAGCTTAAAACAGCAAGCTAGTCAA-3') followed by PCR in the presence of two 
hY5 specific primers: 5'-CTGAATTCAGTTGGTCCGAGTGTTGTGG-3' and the hY5-
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primer mentioned above. PCR products were digested with EcoRI and HindlH and cloned 
into the EcoRI and HindlH sites of pGEM-3Zf(+). 
Mutant hY RNAs were obtained by three approaches: (i) hybridization of the 
oligonucleotide complementary to the S'-end of the hY RNA to the respective hY RNA 
transcribed in vitro followed by incubation in HeLa S100 extract (see: In vitro RNA-S100 
protein binding assay); (ii) Linearization of template DNA for in vitro transcription of hY 
RNA by restriction enzymes recognizing sites in the hY RNA encoding sequence (hYl: 
Spel; hY5: Alul); (iii) Site directed mutagenesis via PCR using alternative primers 
containing single-nucleotide mutations and the hY5 RNA-pGEM-3Zf(+) construct 
described above as template. The predicted secondary structures of the hY RNAs 
produced in vitro and mutants thereof were obtained using the algorithms of Turner et al. 
(1988). 
cDNA cloning 
A human placental Xgtll cDNA library was screened by hybridization with a 5'-
end [32P]-labeled oligonucleotide (5'-CATCAGGGCGCCACTTCAGTTTCCCTC-3') 
derived from a previously published Ro60 cDNA (Deutscher et al., 1988). From the 11 
cDNA clones that were isolated only one (Ro4-7) contained the complete coding sequence 
as established by dideoxy sequencing. The other clones contained partial cDNAs encoding 
C-terminal parts of the protein, e.g. clones Ro7-4 and Ro3-l, which lack nucleotides 
encoding the N-terminal 53 and 274 amino acids, respectively. 
A cDNA containing the complete coding sequence of the La protein was isolated 
out of a human teratocarcinoma cDNA library via an anti-La speciñc autoimmune patient 
serum. 
After recloning the cDNA inserts in pGEM-3Zf(+) sequence analysis revealed 
that these were identical to previously published Ro60 (Deutscher et al., 1988) and La 
(Chambers et al., 1988) cDNAs except for the termini (see Fig. 3). 
S100 extracts 
HeLa S100 extracts were prepared as previously described (Slobbe et al., 
submitted for publication). 
In vitro transcription/translation 
In vitro transcription by T7 RNA polymerase and in vitro translation of the T7-
mRNAs were performed as described by Scherly et al. (1989). Biotinylated and ["P]-
labeled Y and U RNAs were prepared by linearization of the template-plasmids with 
HindlH (unless indicated otherwise) and in vitro transcription in the presence of Biotin-
11-UTP or [а-32Р]АТР, respectively. Wild type and truncated Ro60 and La proteins were 
produced by translation of mRNA in wheat germ extract produced by T7 RNA 
polymerase transcription of template DNA after linearization with Xbal (Ro60wt, Ro7-4, 
Ro3-l, Ro60AA and Ro60AB), TaqI (Ro60AC530), Sad (Ro60AC524), TaqI 
(Ro60AC486), Kpnl (Ro60AC419), PstI (Ro60AC395), HindlH (Lawt and LaAN112), 
BstEH (LaAC293), Xbal (LaAC226), Alul (LaAC202), Ddel (LaAC164), Seal 
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(LaAC136). With the help of the partial R06O cDNAs (lacking sequences that encode N-
terminal parts of the protein: Ro7-4 and Ro3-l) we could demonstrate (see Figure 5B) 
that the most prominent polypeptides migrating faster than R06O in an SDS-
polyacrylamide gel of іл vitro translated protein were produced via internal start-codon 
usage and thus correspond to N-terminal deletion mutants. In Ro60AA and Ro60AB 
internal deletions were created by digestion with Acci and Bgin, respectively, and 
religation. A construct for the production of N-terminally deleted La (LaAN112) was 
obtained by ligating the 1.3 kbp Bglll-Hindm fragment of La-pGEM-3Zf(+) into the 
ВатШ and ffindin sites of A2/3 (Scherly et al., 1989). Translation of this mutant results 
in a truncated La protein where the N-terminal 111 amino acids are replaced by Met-Gly. 
In vitro RNA-S100 protein binding assay 
The analysis of the binding of HeLa S100 proteins to pPj-labeled in vitro 
produced h Y RNAs was performed as previously described (Slobbe et al., submitted for 
publication). 
In vitro transcribed RNA-recombinant protein binding assay 
The analysis of the interaction of recombinant R06O, La and mutants of both 
proteins was performed essentially as described by Scherly et al. (1989). After incubation 
of the p'Sl-labelled recombinant proteins with biotinylated RNA, RNA-protein complexes 
were precipitated with streptavidin-agarose. Precipitated proteins were analyzed by SDS-
polyacrylamide gel electrophoresis. 
Results 
Interaction of HeLa S100 proteins with hYRNAs 
In order to be able to produce the individual hY RNAs in vitro we cloned the hY 
RNA genes in the vector pGEM3-Zf(+). By PCR techniques using hYl and hY3 specific 
primers the hYl and hY3 genes were isolated out of the genomic clone described by 
Wolin and Steitz (1983). The hYS cDNA was obtained by reverse transciption of a Ro 
RNA enriched HeLa cell RNA preparation using an hYS specific primer (based upon the 
hY5 RNA sequence determined by Kato et al., 1982) followed by PCR in the presence of 
two hYS specific primers. In addition to hY specific sequences, primer sequences 
contained restriction enzyme recognition sequences that allowed cloning in the EcoRI and 
Hindm sites of the pGEM3-Zf(+). Due to this cloning procedure T7 RNA polymerase 
transcription of the cloned genes produces wild type hY RNAs with 10 additional 
nucleotides (nts) linked to the S'-ends and S additional nts linked to the 3'-ends. 
Computerized secondary structure predictions for these extended hY RNA molecules 
showed that predicted wild type structures (Wolin and Steitz, 1983; Pruijn et al., 1990) 
are not affected by the extensions. Analysis of these in vitro produced hY RNAs on 
denaturing Polyacrylamide gels demonstrated that these transcripts were of the expected 
size (hYl:128 nts; hY3:117 nts; hY5:99 nts; data not shown, see also Fig 2A). 
The individual hY RNA transcripts ^-labelled) described above were incubated 
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analyzed by immunoprecipi-
tation with either anti-Ro60, 
anti-Ro52 or anti-La specific 
antibodies. The specificity of 
these antibodies has been 
established before (Slobbe et 
al, 1991). This approach 
allows the separate analysis of 
the association of the various 
proteins with the RNAs. The 
results in Figure 1 show that 
all three proteins, R06O, Ro52 
and La are able to assemble 
with all hY RNA transcripts 
under these conditions. The 
specificity of this assay for the 
analysis of reconstituted Ro 
RNPs is illustrated by the lack of precipitated hY RNAs when control antibodies are used 
and when the S100 extract is absent (Figure 1). It should be noted that these results do 
not necessarily mean that a direct interaction of each of these proteins with the RNAs 
occurs. 
Interaction ofHeLa S100 proteins with hY RNAs mutants 
Hybridization of an oligonucleotide complementary to the З'-end of an in vitro 
expressed hY RNA to this RNA prior to the incubation in S100 extract leads to truncation 
of the RNA due to the action of endogenous RNAseH in the S100 extract (Fig. 2B, panel 
a). The efficiency of truncation varies between hYl, hY3 and hY5. Analysis of these 
truncated h Y RNAs on denaturing Polyacrylamide gels showed that the З'-ends of the 
truncated hY RNAs are positioned approximately at hYl nt 98, hY3 nt 87 and hY5 nt 71 
(wild type hY RNA numbering, see Fig. 2A). Immunoprecipitation of these truncated hY 
RNAs via the associated proteins and the respective antibodies described above revealed 
that both R06O and Ro52 binding to all h Y RNAs is abolished by 3'-truncation of the 
RNAs (Fig. 2B, panels b and c, lanes 1-6). The strong signals in lanes 4 (truncated hY3) 
correspond to precipitation of non-truncated wild type hY3. These results are completely 
in agreement with the most highly conserved hY RNA stem structure being the primary 
binding site for Ro antigen(s) as indicated by the RNAse protection experiments of Wolin 
and Steitz (1984). Immunoprecipitation with anti-La antibodies, however, showed that, 
although truncation of hYl interferes with La binding. La is still able to bind to truncated 
hY3 and hY5, albeit less efficiently. Obviously, La does not (only) bind to the presumed 
binding site (the З'-oligouridine stretch) but is also able to interact with other parts of 
hY3 and hY5 (Figure 2B, panel d). For hYl and hY5 RNA these results were confirmed 
using З'-truncated RNAs generated by restriction enzyme digestion of transcription-
template DNA: Spel for hYl leading to a З'-end at position 107; Alul for hY5 leading to 
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Fiç.l. Association ofHeLa SlOO proteins 
•with hY RNAs produced in vitro. 
Radioactively labelled hYl, hY3 or hY5 
RNA, in vitro transcribed by T7 RNA 
polymerase, was incubated with HeLa 
S100 extract. Subsequently, the 
association of the Ro and La antigens with 
the RNAs was analyzed by immuno-
precipitation with mono-specific anti-
R06O, anti-RoS2 or anti-La antibody or 
with normal human control scram. The 
precipitated RNA was examined by 
denaturing Polyacrylamide gel electro-
phoresis followed by autoradiography. 
The upper panel illustrates the inability of 
these antisera to precipitate the Y RNAs 
(added as a mixture) in the absence of 
HeLa S100 proteins. 
70 
Α. 
hY5c 
hYS* 
10 20 30 40 50 60 70 80 90 %M 110 
дддсдмиисСССОввЮСе^СОиАСиСАОииАисиСМШСАТОСии^ 
gggcga*uucGGCOGGtK;CS^UGCAGUGSUCUUUACAA£UAAUUGAUCUCAACCAGUUaCAGAOmjCt^ UGinJCCOUCyCCACUCCCAeUGCmJÇUÇB^JKMAGCa^ 
gggcga*uucAGU0GCOC^JWOGmiGUCOTmjAmjcmj^GOTGA(nJUMCAmroUCU2CCCCCACAACCGCGCinïuASA5etraGCU2t^^ 
gggcg»«uucAuügGeOOCStoG^i™GÖGgGUUAUUGUU^CUUGAiniU^CAIJl«OCUCCCCCCACyUiSCGCGCät^i^ACaroGCUff^ 
gggcgaauu с AG UÜÖeDCe?0lulJuUaGUC5GUUAUUGUUUAGiraOAOtrouAC*O™ïUCU£CCCCC ACAAÇCCCGCOTBS^DfAGCOUGCUGmrouaagcu 
gggcgaauucAGUgGOUCCS^uüGUUG-GSGmJAUUGiro^G0DGAmro^C*mjGUCUeCCCCCACAAQCGCGCOTIGAÍ^GCmJGCUGtnnjua*gcu 
hYSiC9 gggcgaauucAGUÖGe^^iWïUGUOGUG^mjAmJGmj^GÖUGAÜÜU^CAiraGUCUCCCCTCACAACCGCGCOOÖh^AGCtmGCÜGmrouaagcu 
hY5A9 gggcgaauucAGUtKW«C»aMUGUUGUG«UUAUUGtroAAOiroGAmraMCAiraGUCU£CCCCCACAAÇCGCGCOUeA^AGCUUGCUGWrau 
В. 
+ + +
 я 
л л л л л л л л л 
total RNA 
anti-Ro60 
anti-RoS2 
^^шшяшшявшт 
Q ^ V 
anti-La 
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Panel A: The sequences of the transcripts used in the 
RNA-binding assay are listed. Nucleotides 
corresponding to wild type hY RNAs arc in upper 
case, nucleotides derived from vector/linker 
sequences in lower case. Numbering is according to 
wild type hY RNAs (every tenth nucleotide is 
underscored). The most highly conserved regions are 
shaded. The 3' ends of the oligonucleotide/RNase H 
truncated RNAs are indicated by dashed underlining, 
the 3' ends of hYl*SpeI and hY5*AluI by an 
asterisk. Mutated nucleotides in the hYS point 
mutants are indicated by smaller capitals or by dashes 
(single nucleotide deletions). Panel B: Analysis of the 
association of R06O, Ro52 or La with hY RNA 
mutants, as indicated on top of the figure. The 
analysis was performed as described in the legend of 
Figure 1. Panel a shows the RNAs after incubation 
with HeLa S1200 extract. The other panels show 
immunoprecipi-tation results of the RNAs after 
incubation with HeLa S100 extract by monospecific 
anti R06O (panel b), anti-Ro52 (panel c) or anti-La 
(panel d) antibody. The RNAs in the lanes marked 
hYl + 3' oligo, hY3 + 3' oligo and hY5 + 3' oligo 
were hybridized to oligonucleotides complementary to 
the 3' ends of hYl, hY3 and hYS, respectively, 
before incubation with HeLa S100 extract and thus 
are (partially) truncated at the 3' end. 
a З'-end at position 73 (results not shown). 
During the cloning procedure of the hY5 RNA cDNA several clones were 
obtained that contain 2 to 5 point-mutations in comparison with the wild type hY5 RNA 
sequence. The sequence of these hY5 RNA mutants, called hY5a, hY5c and hY5e is 
depicted in Figure 2A. Both hY5a and hY5e contain mutations within the presumed Ro-
protein binding site, while the presumed La binding site in none of these mutants is 
changed. Two additional hY5 point-mutants were constructed in order to investigate 
whether the bulged-C residue, which is part of the presumed Ro-protein binding site, is 
involved in Ro-protein binding. The bulged-C was either deleted (hY5AC9) or altered into 
an Α-residue (hY5A9) via PCR using mutant-primers. Secondary structure predictions for 
all these mutants revealed that the wild type hY5 structure was not severely affected by 
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the mutations. AU mentioned hY5 mutants are efficiently transcribed in vitro as illustrated 
in Figure 2B, panel a. 
The interaction of R06O, Ro52 and La with the hY5 RNA point-mutants was 
analyzed using the immunoprecipitation assay described above. The results, shown in 
Figure 2B, indicate that mutations in the presumed Ro-protein binding site all abolish or 
at least decrease the association with both R06O and Ro52. Most interestingly, a deletion 
of the bulged C-residue completely eliminated Ro-protein association while alteration of 
the bulged С into a bulged A still allows assembly, albeit at a lower efficiency. These 
results confirm that the most highly conserved stem structure of hY RNAs including the 
bulged C-residue is an important determinant for Ro-protein binding. As expected, since 
neither of the hYS point-mutants contains nucleotide changes within the presumed La 
binding site, La interacted efficiently with all of these mutants (Fig. 2B, panel d). 
Interaction of recombinant R06O and La with hY RNAs 
In order to be able to study the macromolecular interactions between Ro RNP 
components in more detail we isolated cDNAs encoding R06O and La out of human 
placental and human teratocarcinomal cDNA libraries. DNA-sequencing showed that 
these cDNAs were identical to those published by Deutscher et al. (1988) for R06O and 
Chambers et al. (1988) for La except for the 5' and 3' termini (see Figure 3). Coding 
sequences are identical to those previously published; the 3' non-coding sequences are 
identical (La) or truncated (R06O) while the 5' non-coding sequences are extended in both 
cases. Remarkably, the 5' non-coding sequence of the R06O cDNA clone is distinct from 
the R06O cDNAs published before (Deutscher et al., 1988; Ben-Chetrit et al., 1989): only 
the first 18 base pairs flanking the ATG start codon are identical. 
The cDNAs obtained were cloned into the EcoRI site of pGEM3-Zf(+). T7 RNA 
polymerase transcription and subsequent translation of the transcripts in wheat germ 
extract in the presence of 35S-Methionine resulted in radiolabeled proteins of the expected 
molecular weights (R06O: 60 kDa; La: 47 kDa). Both the size of the obtained proteins 
and immunoprecipitation experiments using reference anti-Ro and anti-La antisera (results 
K06O сони 1 gMttcgqijCCCCÄCTCCQGCTCTTeCTeTTCCTirrecCTaTCOCTOCeC 50 
S I CTCACOCnCCI ЖТТТСеСАПСССТОСОСАССАСТТСТССТ 100 
191 CftCAMJUÜUUt КТО O K CAÁ TCT OTA 
1B48 CCAGCTIbATCTCCACCCAATaAATGATCATGCTAecc9**ttc 1890 
1727 » TACTATCTCCATAATC 177« 
Fig.3. Structure of the cDNAs encoding 
RoóOandLa, 
The sequence of our R06O cDNA clone 
(1.) ia compared with that of a previously 
published R06O cDNA (Deutscher et al., 
1988; 2.)· Similarly, the sequence of our 
La cDNA clone (3.) is compared with that 
of Chamber* et al. (1988) (4.). Identical 
nucleotides are indicated by dashes. 
Central cDNA parts indicated by dots are 
completely identical. In the R06Û cDNAi 
triplets mark the coding region. 
1 gaittccCCGCTTTAGCCTCCCCGGCGCCCCTCCCAC. , gg*attc 1664 
,. 1631 
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Fig.4. Analysis of the interaction of recombinant Ro60 with hYRNA. 
Recombinant Ro60 was translated in wheat germ extract in the presence of L-p5S]-methiomne, incubated with 
biotinylated RNA and precipitated with streptavidin-agarose. Precipitated proteins were analyzed by SDS-PAGE 
followed by autoradiography. Panel A: Wild type Ro60 was incubated with biotinylated RNA as indicated on top of the 
panel. The lane marked Ro60 contains 25% of the input protein. Panel B: RNA binding of Ro60 deletion mutants. In 
the lanes marked Ro3-l and Ro7-4 translates obtained by translation of mRNA derived from Ro60 cDNA clones Ro3-l 
and R07-4, respectively, are shown. The position of N-terminal Ro60 deletion mutants is indicated on the left. The 
binding of Ro60 (or Ro60 deletion mutants) to hYl and U2 RNA was analyzed. Each set of three lanes contains 25% of 
input protein (marked input), protein bound by hYl RNA (marked hYl) and protein bound by U2 RNA (marked U2). 
The positions of C-terminal and internal deletion mutants are marked by asterisks. Wild type Ro60 was added as an 
internal positive control to the deletion mutant analyses, except for the analyses of Коб0ДС530 and Ro6(№C524. The 
band at about 45 kDa co-occurring with RNA-bound Ro60 is due to Ro60 degradation after the RNA binding assay. 
Panel C: Structure of the Ro 60 deletion mutants and summary of the RNA-binding analyses. The Ro60 protein (538 
amino acids) is drawn schematically. The positions of Ihe RNP-80 motif and the putative zinc finger are indicated. The 
first and last amino acid of N- and C-terminal deletion mutants are indicated by flags. The numbers refer to the position 
of these amino acids in the wild type protein. White flags indicate the ability to bind hYl RNA; Grey flags indicate lack 
of RNA binding. The structure of the internal deletion mutants ΕοδΟΔΛ and КобОДВ (both unable to bind RNA) is 
illustrated by the black bars. 
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not shown) confirm that our cDNAs encode genuine R06O and La polypeptides, 
respectively. 
In order to study the interaction of recombinant proteins with the h Y RNAs we 
employed the assay described by Scherly et al. (1989). In short, biotinylated RNA is 
incubated with radiolabeled protein translated in vitro and protein-RNA complexes are 
precipitated with streptavidin-agarose. Finally, precipitated protein is analyzed by SDS-
PAGE. The results in Figure 4A show that R06O specifically interacts with hYl, hY3 and 
hY5 RNA and not with control RNAs (Ul, U2) nor with the the 3' truncated hYl*SpeI 
mutant. Thus, the binding specificity of recombinant R06O is identical to what was 
observed when HeLa S100 was used as protein source. 
We next wanted to analyze which parts of R06O are involved in RNA binding. 
As has been documented by Deutscher et al. (1988) and Ben-Chetrit et al. (1989) at the 
primary sequence level two (potentially nucleic acid binding) motifs can be discerned. 
One of these, the RNP motif (Scherly et al., 1990), has been found in many RNA-binding 
proteins and, in some cases, has been shown to be directly involved in the interaction 
with U RNAs (Scherly et al., 1990; Nagai et al., 1990). The second motif strongly 
resembles a so-called zinc-finger, which is involved in the interaction of a number of 
DNA-binding proteins with DNA (Berg, 1990). 
Several R06O deletion mutants were produced in vitro and the binding of these 
mutants to hYl and U2 RNA (as a control) was assayed as described above. When 
mutant was clearly separated from wild type R06O (all except Ro60ACS30 and 
Ro60ACS24) full length R06O was included in the assays as an internal positive control. 
The results in Figure 4B show that all deletions eliminated the capacity of R06O to bind 
specifically to hYl RNA. Even an N-tenninal deletion of 29 amino acids or a C-terminal 
deletion of only 8 amino acids resulted in the loss of binding (Figure 4C). Since it is not 
very likely that both extreme termini of R06O are directly involved in the interaction with 
RNA, these results suggest that the presence of both termini is a prerequisite for 
maintaining a conformational structure that is indispensible for RNA binding. 
The approach used to study the interaction of recombinant La with h Y RNA was 
analogous to the one described above for the R06O-RNA interaction. The results shown in 
Figure 5A show that La specifically interacts with hYl, hY3, hY5 and Ul RNA but not 
with hYl*SpeI nor with U2 RNA. These data indicate that the RNA-binding specificity of 
recombinant La in this assay reflects the specificity of native La in S100 extracts. 
hYl and U2 RNA were selected for the analyses of the RNA-binding capacity of 
La deletion mutants, in order to study which parts of La are essential for the interaction 
with RNA. At the primary sequence level an RNP motif has been found in La as well 
(Figure 5C; Chambers et al., 1988). Several La deletion mutants were produced in vitro 
and the effects of these deletions on RNA-binding of La were analyzed (Figure SB). C-
terminal deletion-mutants containing an intact RNP domain were all able to bind hYl 
RNA, but deletions affecting the RNP motif eliminated its RNA-binding capacity. 
However, the result of the N-terminal deletion mutant shows that the presence of the RNP 
motif alone is not sufficient for RNA binding of La. These results strongly suggest 
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Fig.S. Analysis of the interaction of recombinant La with hYRNA. 
Recombinant La was translated in wheat germ extract in the presence of L-[J5S]-methionine, incubated with biotinylated 
RNA and precipitated with streptavidin-agarose. Precipitated proteins were analyzed by SDS-PAGE followed by 
autoradiography. Panel A: Wild type La (lane marked La contains 25% of input protein) was incubated with the RNAs 
as indicated on top of the panel. Polypeptides migrating faster than La represent degradation products of La. Panel B: 
RNA-binding of La deletion mutants. Each set of three lanes contains 10% of input protein (marked input), protein 
bound by hYl RNA (marked hYl) and protein bound by Ш RNA (marked Ш). The positions of N- and C-terminal 
deletion mutants are indicated by asterisks. Wild type La was added as a positive internal control to the deletion mutant 
analyses. Panel C: Structure of La deletion mutants and summary of RNA-binding analyses. The La protein (408 amino 
acids) is drawn schematically. The position of the RNP-80 motif is indicated. The first and last amino acid of N- and C-
terminal La deletion mutants, respectively, are indicated by flags. The numbers refer to the position of these amino 
acids in the wild type protein. White flags indicate the ability to bind hYl RNA; Grey flags indicate lack of RNA 
binding. The region of La required for RNA-binding is shown below. 
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that the minimal RNA-binding region of La consists of the RNP motif and the adjacent 
part of the N-terminus of the protein (Figure 5C). 
Discussion 
RNA-protein interactions occurring within Ro RNP particles have been analyzed. 
Reconstitution of Ro RNPs by incubation of in vitro transcribed hY RNAs in HeLa S100 
extract followed by immunoprecipitation with monospecific antisera proved to be a very 
specifìc and sensitive way to analyze the effects of RNA mutations on the association of 
the individual proteins with these particles. In order to study regions of the proteins 
involved in RNA-binding in more detail we isolated and cloned cDNAs encoding R06O 
and La and used these for in vitro expression of the corresponding proteins. The 
interaction of these proteins and mutants thereof with biotinylated hY RNAs was analyzed 
by precipitation with streptavidin-linked agarose beads as described by Scherly et al. 
(1989). The results of both approaches unambiguously show that R06O and La directly 
bind to hY RNAs. 
The RNA binding site for R06O and La 
Previous RNase protection experiments (Wolin and Steitz, 1984) have shown that 
the most highly conserved region of the human Y RNAs is protected against degradation, 
presumably by bound Ro antigenic protein(s). In agreement with data from Deutscher et 
al. (1988), who showed that recombinant R06O is able to bind hYl RNA, the results of 
our reconstitution experiments, using either HeLa S100 extract as protein source or in 
vitro expressed recombinant R06O, indicate that R06O is the protein that directly binds to 
the most highly conserved region of hY RNAs. Moreover, the bulged C-residue present 
in this region seems to be an important determinant for this interaction since both deletion 
and alteration of the bulged С severely affected binding. The importance of bulge 
structures for the interactions of proteins with RNA has been found in other systems as 
well. For example, the interaction of the bacteriophage R17 coat protein with the RNA is 
dependent on the presence of a single bulged A residue (Wu and Uhlenbeck, 1987) while 
a bulge structure in HIV-1 TAR RNA is required for binding of the viral Tat protein 
(Roy et al., 1990). Our results do not completely rule out the possibility that also Ro52 
interacts with the same region of hY RNAs. However, the results of further experiments, 
to be published elsewhere (Slobbe et al., submitted for publication), show that RoS2 is 
completely dependent on the presence of R06O for its association with hY RNAs and that 
a direct protein-protein interaction between R06O and Ro52 can be observed, even in the 
absence of RNA. We conclude that R06O directly interacts with the most highly 
conserved region of hY RNAs. 
The lack of interaction of both S100- and recombinant R06O with the hYl mutant 
terminating at nucleotide 107 (hYl*SpeI) is somewhat puzzling because the complete 
conserved region of the R06O binding site is present and because hY2, a truncated version 
of hYl occurring in vivo which terminates between nts 103 and 107, is precipitable from 
cell extracts with anti-Ro60 antibodies (Hendrick et al., 1981: Wolin and Steitz, 1983). 
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The most plausible explanation for this discrepancy is that hYl might be cleaved in 
cell(extract)s while it is bound by R06O, thereby not affecting the binding of the protein. 
Alternatively, the secondary/tertiary structure of the truncated hYl RNA made in vitro 
might be such that it does not allow R06O to bind. 
The La protein is generally believed to bind to the common sequence motif 
present in La-associated RNAs, a short stretch of uridylate residues at the 3' terminus of 
the RNA. Indeed, evidence for this motif being the site of interaction with the La protein 
has been obtained (Stefano, 1984; Mathews and Francoeur, 1984). Since none of our in 
vitro transcribed RNAs contains an oligouridylate stretch positioned at the З'-end of the 
molecule, our data show that La is also able to interact with RNAs lacking this motif. 
Nevertheless, most La binding RNA molecules analyzed do contain an oligouridylate 
stretch near the 3' terminus and deletion of these nucleotides in hYl impaired La binding, 
suggesting that this sequence motif should not necessarily be located at the extreme 3'-end 
of the RNA molecule for La to bind. At present we are investigating whether La binds 
with different affinities to oligouridylate stretches at the 3' end of the molecule compared 
to those flanked on both sides by other nucleotides. That the La binding site might be 
even less stringently defined is illustrated by the binding of La to truncated hY3 and hY5 
RNAs lacking the U4 stretch near the 3' end. At present, it is not known whether La in 
these cases recognizes other internal oligouridylate stretches (Uj and U2 stretches are 
present in hY3 and hY5, but also in hYl) or whether completely divergent sequences are 
bound. Interestingly, La does also interact with Ul RNA both in vitro (Fig. SA) and in 
vivo (Madore et al., 1984). 
Regions ofRoóO and La required for RNA binding 
Both R06O and La contain an amino acid sequence motif, mostly referred to as 
RNP motif, RNA binding domain or RNA recognition motif, often found in RNA binding 
proteins (Bandziulis et al., 1989; Query et al., 1989; Scherly et al., 1990). In several 
cases, e.g. poly(A) binding protein (Sachs et al., 1987), U1-70K (Query et al., 1989), 
Ul-A (Scherly et al., 1989) and U2-B" (Scherly et al., 1990), this RNP motif with only a 
few flanking amino acids has been shown to be sufficient for specific RNA binding. In 
this paper we have shown that for hY RNA binding of R06O as well as La much larger 
parts of the RNP motif flanking sequences are required. While for La C-terminal 
deletions up to the RNP motif, which ranges from amino acid 112 to amino acid 187, are 
allowed all deletions in R06O, containing the RNP motif from amino acid 92 to amino 
acid 161, abolished its capacity to bind RNA. These observations might be explained by 
two phenomena: (i) In addition to the RNP motif other amino acid motifs might be 
directly involved in and absolutely required for the interaction with RNA. (ii) Other parts 
of the protein, while not having a direct role in the interaction with RNA, might be 
required for the RNP motif to fold properly. Although the putative zinc finger, a motif 
found to be important for the interaction of a number of DNA-binding proteins with 
DNA, of R06O is a good candidate for a motif being also directly involved in RNA-
binding we do not favour this hypothesis since deletions not affecting either the zinc 
fìnger or the RNP motif still abolished RNA binding and because the zinc finger region of 
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Ro60 is already directly involved in the interaction with Ro52 (Slobbe et al., submitted). 
The R06O protein binds a region of h Y RNAs which is predicted to adopt a 
primarily double-stranded structure. In this respect R06O deviates from other RNP 
containing RNA-binding proteins, because poly(A) binding protein, Ul-70k, Ul-A, U2-
B" and La all have been shown to interact with at least partially single-stranded regions of 
the respective RNAs (Stefano, 1984; Sachs et al., 1987; Query et al., 1989; Scherly et 
al., 1989 and 1990). 
Several reports have shown evidence for the heterogeneity of Ro RNPs (for 
review see Pruijn et al., 1990). The data presented in this paper and the data presented by 
Slobbe et al. (submitted), indicating that R06O, Ro52 as well as La are able to associate 
with all h Y RNAs (a similar binding of both R06O and La to the recently sequenced hY4 
(O'Brien and Harley, 1990) may be predicted based upon sequence homology), can not or 
only partially explain differences in protein composition of the individual Ro RNPs. The 
putative binding of a second La polypeptide to hY3 and hY5 RNP but not to hYl RNP 
may be responsible for heterogeneity but does not reflect the apparent differences in 
molecular weight of Ro particles in gel filtration nor their different behaviour during 
biochemical fractionation (Boire and Craft, 1990). Possibly other, yet unidentified 
proteins are associated with Ro RNPs as well. Interestingly, a third conserved sequence 
motif has been identified within the hY RNAs (Pruijn et al., 1990). Although a weak 
interaction of Ro52 with this motif can not be excluded yet, it might be the recognition 
site of another protein as well. Since the position of this motif relative to the motif 
determining R06O binding differs in hYS compared to the other hY RNAs (in hYS both 
motifs are overlapping), this might explain heterogeneity to some extent. The 
identification of an hY5 RNP specific epitope (Boire and Craft, 1989) might be easily 
explained by the binding of an hY5 RNP-specific protein, bearing the epitope, to this 
particle. The assays described in this paper to study the Ro RNP structure already have 
(Slobbe et al., submitted) and will be helpful to study the Ro RNP structure in more 
detail and to unravel differences in the molecular composition of the various Ro RNPs. 
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Abstract 
The human Y RNAs, small RNAs with an unknown fiinction, are complexed with 
at least three proteins: the 60 kDa Ro protein (R06O), the 52 kDa Ro protein (Ro52) and 
the La protein (La). In this study we examined the intermolecular interactions between the 
components of these so-called Ro ribonucleoprotein (Ro RNP) complexes. 
Incubation of ^PJ-labelled hYl RNA in HeLa S100 extract allows the 
reconstitution of Ro RNP complexes, which was analyzed by immimoprecipitation with 
monospecific antisera. By immunodepletion of HeLa S100 extracts for either R06O, Ro52 
or La, followed by suppletion with recombinant R06O or La, it was demonstrated that 
both R06O and La bind to hYl RNA directly without being influenced by one of the other 
proteins. However, binding ofRo52 to hYl required the presence ofRoóO, indicating the 
association ofRo52 with hYl RNA via R06O. 
To Jurther define the protein-protein interaction between R06O and Ro52, f'SJ-
labelled R06O deletion mutants were incubated in HeLa S100 extract followed by 
immimoprecipitation with monospecific anti-Ro52 antibody. This approach allowed the 
identification of a region ofRoóO (amino acids 276-318) responsible for binding to Ro52. 
The protein-protein interaction between R06O and Ro52 was found to be RNA 
independent, since reconstitution ofRo60-Ro52 complexes in micrococcal nuclease treated 
HeLa S100 extracts yielded identical results. The RNA independency of the interaction 
between R06O and Ro52 is jurther supported by the fact that R06O deletion mutants, not 
capable of binding to hYRNA, still are able to bind to Ro52. 
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Introduction 
Autoantibodies to the Ro (SS-Α) and the La (SS-B) ribonucleoprotein complexes 
(RNPs) are found in sera from patients with systemic lupus erythematosus and Sjogren's 
syndrome (reviewed by Chan and Tan, 1989). Such patient autoantibodies have been of 
great value in the identification and characterization of these RNA-protein complexes. 
La RNPs are composed of a single RNA polymerase III transcript, that is bound 
through its З'-uridine stretch to the 46.7 kDa La protein (La). This protein is highly 
conserved among mammalian species and contains the antigenic determinants of the 
complex. La belongs to a family of RNA binding proteins sharing an 80 amino acids 
domain, referred to as RNA recognition motif, RNA binding domain or, more neutrally, 
RNP-80 motif (Bandziulis et al., 1989; Query et al., 1989; Scherly et al., 1989). The La 
protein functions as an RNA polymerase III transcription termination factor (Gottlieb and 
Steitz, 1989a,b) and is predominantly localized in the nucleus (for review see Pruijn et 
al., 1990). 
Although the function of the Ro RNPs still is a mystery, several studies on the 
structure of Ro complexes have been performed. In human cells four Ro RNAs have been 
described (hYl, hY3, hY4 and hY5), varying in length between 84 and 112 nucleotides 
(for review see Pruijn et al., 1990). The hY RNAs have been sequenced and secondary 
structures have been predicted (Kato et al., 1982; Wolin and Steitz, 1983;the O'Brien and 
Harley, 1990; Pruijn et al., 1990). The lower part of the characteristic stem structure 
structure of all Y RNAs contains a highly conserved region, which was shown to be 
protected against RNAse degradation presumably by bound protein(s) (Wolin and Steitz, 
1984). The protein content of the Ro RNP complexes consists of at least two Ro proteins 
with molecular weights of 60 kDa (Ro60) and 52 Ша (Ro52), respectively. Since the 
RNAs are transcribed by RNA polymerase III, they become associated with the La 
protein as well (for review see Pruijn et al., 1990). Complementary DNAs containing the 
complete coding sequence of Ro60 have been isolated (Deutscher et al., 1988; Ben-
Chetrit et al., 1989) and the recombinant Ro60 protein was shown to associate with hYl 
RNA in vitro (Deutscher et al., 1988). Ro60 is also a member of the RNA binding 
protein family sharing an RNP-80 motif. Recently, cDNA clones encoding Ro52 have 
been described as well (Chan et al., 1991; Itoh et al., 1991). An RNP-80 motif has not 
been found in Ro52 and, although affinity purified anti-Ro52 antibody was able to 
precipitate the characteristic hY RNAs, no direct interactions between Ro52 and the Ro 
RNAs were identified. Apart from these two main antigenic Ro proteins, other putative 
Ro proteins have been described. Two of these, with molecular weights of 60 and 54 
kDa, are found in red blood cells only and thus might be tissue specific Ro components 
(Rader et al., 1989). Another putative Ro component, the human analogue of calreticulin 
(McCauliffe et al., 1990), has been described, but its involvement in the complexity of 
Ro RNPs is as yet not clear. 
To gain insight into the structure of the Ro RNP complexes, a series of 
experiments were performed which showed that only Ro60 and La bind directly to hYl 
RNA and that Ro52 binds indirectly to hYl RNA via Ro60. 
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Materials and methods 
Cloning and expression ofRoóO and La in E. coli 
Full length cDNAs coding for R06O and La were obtained by screening a human 
placenta Xgtll library with specific oligonucleotides (R06O) or a human teratocarcinoma 
Xgtll library with a patient autoimmune serum (Pruijn et al., manuscript in preparation). 
The R06O coding sequence was identical to the one published by Deutscher et al. (1988), 
whereas the sequence of La was identical to the one published by Chambers et al. (1988). 
The cDNAs encoding R06O and La were mutated in order to clone the complete coding 
sequences in vector pET8c (Studier et al., 1990) by PCR using mutated oligonucleotides 
without changing the amino acid sequence of both proteins. The resulting product (see 
Figure 1) was ligated in vector pET8c and transfected into E. coli strain BL21 (DE3) 
pLysS. 
The transformed bacteria were grown until an ΟΌ550 of 1.0 in LB medium (10g 
Bactotryptone, Sg Yeast extract and 10g NaCl per liter with 200 /ig/ml ampicilline and 30 
ßg/ml chloroamphenicol) was reached. Subsequently, protein expression was induced by 
adding isopropylthiogalactoside (IPTG; final concentration 0.5 mM) to the medium. After 
3h of induction the bacteria were harvested and either dissolved in 1/10 volume of SDS-
sample buffer (2% Sodium dodecyl sulphate/ 5% ß-mercaptoethanol/ 10% glycerol/ 
0.005% bromo-phenolblue/50 mM Tris HCL pH6.8) for gel analyses or lysed in 1/10 
volume of PBS by repeated freezing and thawing for suppletion studies. 
In vitro transcription and translation 
For in vitro transcription and translation of R06O, the cDNA encoding R06O was 
ligated in vector pGEM3z-f(+) in order to produce mRNA by T7 RNA polymerase 
transcription. For the transcription of hYl RNA the coding sequence of the hYl gene 
(Wolin and Steitz, 1983) was amplified by PCR techniques and ligated into vector 
pGEM3z-f(+). T7 RNA polymerase transcription of this construct yields hYl RNA with 
10 additional nucleotides at the 5' end and 5 nucleotides at the 3' end. The predicted 
secondary structure of this transcript is identical to the secondary structure of the wild 
type hYl RNA and, as will be shown below, R06O, Ro52 and La are able to bind 
specifically to this RNA (Figure ЗА). 
In vitro transcription was performed as follows: To produce mRNA for in vitro 
translation 2 μg of linearized template was incubated at 37 "C for 60 min in a total 
volume of 50 μ\ containing: 40 mM Tris-Cl pH 7.9, 6 mM MgC^ 10 mM spermidine-
HCL, 10 mM NaCl, 2 mM dithiothreitol (DTT), 0.1 mg/ml BSA, 60 μΜ GpppG, 1 mM 
ATP, UTP, CTP and GTP, 60 U RNAse inhibitor (Promega) and 30 U 17 RNA 
polymerase (Promega). In order to produce ["PJ-labelled hYl RNA 0.5 μg template DNA 
was transcribed in a total volume of 20 μΐ (same buffer as described above) with 20 μΟ 
a[3íP]-UTP (Amersham, UK, 3000 Ci/mmol), 0.12 mM UTP and 1 mM ATP, GTP and 
CTP. After transcription unincorporated nucleotides were removed by a Sephadex G50 
spin column, the RNA was phenol extracted, ethanol precipitated and dissolved in 10 μΐ 
(mRNA) or 100 μΐ ([32P]-hYl RNA) sterile water. 
85 
In vitro translation was performed by incubating 1 μΐ in vitro transcribed mRNA 
for 60 min at 25 "C in a total volume of 30 μΐ containing 15 μΐ Wheat Germ Extract 
(WGE, Amersham, UK), 120 mM potassium acetate, 67 μΜ of 19 amino acids mixture 
minus methionine and 30 μ€ϋ L-^SJ-methionine (1200 Ci/mmol, Amersham, UK). 
Antibody purification 
Antisera monospecific for Ro60 or La polypeptides were isolated by immuno-
affinity chromatography using bacterially expressed antigens. A monospecific anti-Ro52 
patient antibody (JoT) was passed over a recombinant Ro60 column to remove possible 
trace amounts of anti-Ro60 antibody. The resulting antibody preparations were checked 
for their monospecificity on Western blots containing HeLa cytoplasmic extract, on 
Western blots containing recombinant Ro60 or La and by immunoprecipitation of f2?]-
labelled cellular extracts, as described earlier (Slobbe et al., 1991a and b). For the 
identification of recombinant Ro60 and La well characterized autoimmune patient sera 
were used (references were obtained from the Center for Disease Control, Atlanta, 
Georgia, USA). 
Preparation of extracts 
For the binding of HeLa proteins to in vitro transcribed [32P]-hYl RNA we used 
HeLa S100 extract as protein source: Approximately 2*10? HeLa S3 suspension cells 
were washed twice with PBS pH 7.2 and resuspended in S100 buffer (25 mM Tris-Cl, pH 
7.4, 0.1 mM EDTA, 0.25 mM DTT, 0.5 mM PMSC, 0.1 M KCl, 0.01% Nonidet-P40 
and 20% glycerol) at 1*10' cells/ml. After 15 strokes with a Dounce homogenizer the 
suspension was centrifuged at 1000g for 10 min. The pellet was again centrifuged at 
25000g for 20 min and the additional small amount of supernatant was carefully removed. 
The combined supematants were then centrifuged at 108,000g for 60 min and the 
resulting S100 extract was stored in aliquots at -70 0C. 
HeLa S100 extract was immunodepleted by five consecutive rounds of 
immunoprecipitation with monospecific antisera bound to protein Α-agarose in the 
presence of 300 mM sodium chloride. The efficiency of depletion was monitored by 
Western blotting (see Figure 3B). 
Binding assays 
Reconstitution of Ro RNP complexes was performed by adding 1 μΐ pPJ-hYl 
RNA (approximately 30,000 cpm) to 15 μΐ S100 extract in a total volume of 25 μΐ, 
containing 2.5 mM MgClj, 150 mM NaCl and 5 μg tRNA. After 30 min of incubation at 
20 "C, reconstituted Ro RNP complexes were immunoprecipitated with monospecific 
anti-Ro60, anti-Ro52 or anti-La antibody bound to protein Α-agarose in the presence of 
150 mM NaCl and the precipitated RNA was analyzed by gel analysis as described before 
(Slobbe et al.,1991b). 
To elaborate the protein-protein interaction between Ro60 and Ro52, WGE 
translated [35S]-labelled Ro60 deletion mutants were incubated in HeLa S100 extract as 
described above and immunoprecipitated by monospecific anti-Ro52 antibody in the 
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presence of ISO mM NaCl. After immunoprecipitation, RoS2 bound ['5S]-labeled R06O 
deletion mutants were analyzed by SDS-polyacryl-amide gel electrophoresis. After 
electrophoresis the gel was fixed, treated with Amplify (Amersham, UK), dried and 
autoradiographed using Kodak XAR5 film at -70 "C. 
Results 
Expression ofRoóO and La polypeptides 
Complementary DNAs containing the complete coding sequence of R06O and La 
were mutated at the 5' border of the coding region, creating a Ncol restriction site, and in 
the 3'-non-coding sequence, creating a BamHI and Hindin site, respectively. These 
changes facilitated cloning of the cDNAs in vector pET8c (Studier et al., 1990) for 
expression of the respective non-fusion proteins in E. coli (see Figure 1). 
R06O: 
M E E S I * 
5 ' -ACAAAAAASSMQGAGGAATCTG—1S98 nt—ATTTAAGCATAAGCAGCAGCASOATCCS-3 ' 
La: 
Μ Α Ε N D Q * 
5 ' -GATAGCCGC£AXGOCTGAAAATG—1205 nt—GACCAGTAGTTTAGTAAACCAAGÇTTTT-3 ' 
Fig.l. Mutations in the cDNAs encoding R06O and La. 
Full length cDNAs coding for R06O and La were obtained aa described in Materials and Methods. Mutations 
in the cDNAa generated by PCR aie underlined, restriction sites created by these mutations are printed bold. 
The protein sequences are shown above the DNA sequence. Asterisk refera to termination codon. 
After induction of recombinant protein expression and lysis of the bacteria the 
expression of R06O and La was analyzed on an SDS-polyacrylamide gel (Figure 2A). The 
antigenicity of the recombinant proteins was confirmed on Western blots using well 
characterized anti-Ro60 (Figure 2B, left panel) and anti-La (Figure 2B, right panel) 
autoimmune sera. 
Ro RNP reconstitution in HeLa S100 extract 
To analyze RNA-protein interactions in Ro RNP complexes in vitro, T7 RNA 
polymerase transcribed [^-labelled hYl RNA was incubated in HeLa S100 extract. 
Subsequent immunoprecipitation with monospecific antibody in the presence of ISO mM 
NaCl allows the identification of proteins that are complexed with the RNA. The results 
of such a reconstitution assay show that monospecific anti-Ro60, anti-Ro52 and anti-La 
antibodies are able to precipitate the Ro RNP complexes formed during incubation (Figure 
ЗА). The efficiency of reconstitution and subsequent immunoprecipitation generally varied 
between S and 10% of the input [^Pj-hYl RNA when anti-Ro60 and anti-RoS2 antibody 
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Fig. 2. Induction ofRo60 and La expression in Escherichia coli. 
panel A: Coomaasie Brilliant Blue stained Polyacrylamide gel containing extracts of non-induced (lane 1) and 
IFTG-induced bacteria (lane 2) transformed with Ro60 pETSc. In lane 3 extract of non-induced and in lane 4 
extract of induced £. coli transformed with La pETSc was loaded. Bands corresponding to recombinant Ro60 
or La are indicated on the right, the position of markers is shown on the left, panel B: Immunoblots of gels 
identical to the gel shown in panel A, incubated with anti-Ro (left) or anti-La (right) reference serum. 
and between 15 and 20% when anti-La antibody was used. 
Ro RNP reconstitution in immunodepleted HeLa S100 extracts 
HeLa S100 extracts were depleted for R06O, Ro52 or La by the procedure 
described in Materials and Methods. The efficiency of immunodepletion was tested by 
immunoblotting using a serum containing antibodies to R06O, Ro52 and La (Figure 3B). 
An extract was used only when no residual antigen could be detected on the Western blot. 
Immunodepletion with normal human serum did not have any effect (lane 1). 
Subsequently, the extracts immunodepleted for either R06O, Ro52 or La were 
used for the reconstitution of Ro RNP complexes with in vitro transcribed [32P]-labelled 
hYl RNA. The "depletion"-procedure of HeLa S100 extract with normal human serum 
did not have any influence on the binding of Ro and La proteins to hYl RNA (results 
identical to those shown in Figure ЗА). The removal of R06O from HeLa S100 extract not 
only resulted in the loss of the formation of anti-Ro60 antibody precipitable Ro RNP 
complexes, but hYl RNA-precipitation via anti-Ro52 antibody was abolished as well, in 
spite of the fact that Ro52 is still present in the extract (Figure 3C, lanes 2 and 3, left 
panel). The binding of La to hYl RNA is not influenced by the absence of R06O (Figure 
3C, lane 4, left panel). 
Depletion of Ro52 from HeLa S100 extract of course abolished its binding to 
hYl RNA (figure 3C, middle panel, lane 3) but did not interfere with the binding of 
either R06O or La to hYl RNA (Figure 3C, middle panel, lanes 2 and 4). Similarly, 
depletion of La from HeLa S100 extract precluded the formation of La-hYl RNA 
complexes (Figure 3C, right panel, lane 4), but did not influence the binding of either 
R06O or Ro52 to hYl RNA (Figure 3C, lanes 2 and 3, right panel). 
These findings suggest that (i) R06O binding to hYl RNA is independent of both 
La and Ro52, (ii) for Ro52 binding to hYl the presence of R06O is required and (iii) the 
binding of La to hYl RNA is not dependent on the presence of the Ro proteins. 
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Fig.3. Analysis ofRo RNP complexes reconstituted in HeLa SlOO extracts. 
pand A: I , 2 P| labelled in vitro transcribed hYl RNA was incubated in HeLa SIGO extract and subsequently 
immunoprecipitated with normal human serum (lane 1), anti Ro60 (lane 2), anti-RoS2 (lane 3) or anti-La 
antibody (lane 4). Total immunoprecipitated RNA was analyzed on a 10% polyacrylamide-urea gel and 
autoradiographed. panel B: After immunodepletion of HeLa S100 extracts with monospecific anti-La (lane 2), 
anti-Ro52 (lane 3) or anti-Ro60 (lane 4) antibody the extracts were analyzed via immunoblotting using a 
reference serum containing antibodies to Ro60, RoS2 and La. Control S100 extract immunodepleted with 
normal human serum is shown in lane 1. Positions of Ro60, Ro52 and La are indicated on the right, panel C: 
Immunodepleted HeLa S100 extracts as indicated on top of each panel were used for the reconstitution of Ro 
RNP complexes with ["PJ-labelled hYl RNA. The RNPs were immunoprecipitated with either normal human 
serum (lanes 1), anti-Ro60 (lanes 2), anti-Ro52 (lanes 3) or anti-La (lanes 4) antibody and the precipitated 
RNA was analyzed on a denaturing polyacrylamide-urea gel. 
Supplementation of immunodepleted HeLa S100 extracts with recombinant R06O and La 
To further define the requirement for R06O of Ro52 to bind to hYl RNA, 
bacterially expressed R06O was added to Ro60-depleted HeLa S100 extract. As shown in 
Figure 4A, addition of recombinant R06O restored both binding of R06O and binding of 
Ro52 to hYl RNA (right panel, lanes 2 and 3). Addition of control bacterial extract, 
containing neither R06O nor La recombinant protein, had no effect (left panel). The 
addition of recombinant R06O had no effect on the binding of La to hYl RNA (Figure 
4A, compare lanes 4). 
To control the specificity of the reconstitution, recombinant R06O was added to 
Ro52-depleted S100 as well (Figure 4B, right panel). As expected, there was no effect on 
the efficiency of La or RoS2 binding (lanes 3 and 4), but a slightly diminished 
precipitation of hYl by anti-Ro60 antibodies was reproducibly observed (Figure 4B, lanes 
2, right vs. left panel). This can be explained by the presence of excess R06O, only 
partially complexed to hYl RNA and competing for the anti-Ro60 antibodies. 
Addition of recombinant La to La-depleted HeLa S100 extract restored the La-
Fig. 4. Supplementation af monunodepleted HeLa 
S100 extracts with recombinant RoóO and La. 
Reconstitution of Ro RNP complexes was 
performed with immunodepleted HeLa S100 
extracts and [ ' Ï l-hYl RNA, supplemented with 
bacterial extracts containing recombinant R06O or 
La protein or with control bacterial extracts as 
indicated on top of each panel. In panel A R06O-
depleted S100 was used, in panel В RoS2 depleted 
S100 and in panel С La depleted 5100 extract. In 
lanes 1 normal human serum precipitations, in lanes 
2 immunoptecipitations with anti-Ro60 antibody, in 
lanes 3 anti-Ro52 antibody precipitations and in 
lanes 4 anti-La antibody immunoprecipitations were 
performed. After reconstitution and immune-
precipitation, total precipitated RNA was analyzed 
on a polyacrylamide-шеа gel. 
hYl RNA interaction without affecting R06O or Ro52 binding (Figure 4C, lanes 4, left 
vs. right panel). 
The results described above corroborate the earlier finding that the association of 
Ro52 with hYl RNA depends on the presence of R06O, whereas the binding of both R06O 
and La to hYl RNA is not influenced by the presence of one of the other proteins. This 
suggests that R06O either induces a conformational change of the RNP thereby enabling 
Ro52 to associate with the complex or that Ro52 binds directly to R06O in Ro RNP 
complexes. 
Binding of recombinant R06O to Ro52 in HeLa S100 extract 
To substantiate the presumed interaction between R06O and Ro52 in Ro RNP 
complexes, in vitro translated p'SJ-methionine labelled R06O protein was incubated with 
HeLa S100 extract and immunoprecipitated by anti-Ro52 antibody in the presence of 150 
mM NaCl (Figure 5A, lane 1). As a control a similar precipitation was performed in the 
absence of HeLa S100 extract (Figure 5A, lane 2). The results show that R06O can be 
precipitated by anti-Ro52 antibodies only in the presence of factors (i.e. Ro52) contained 
in the S100 extract. 
To test whether the Ro52-Ro60 interaction is dependent on the presence of RNA, 
HeLa S100 extract was pre-treated with micrococcal nuclease. After this treatment no h Y 
RNAs could be detected any more when a Northern blot of this nuclease treated extract 
was probed with anti-sense hYl, hY3 or hY5 RNA (data not shown). However, in vitro 
translated R06O was still precipitated efficiently by anti-Ro52 antibodies (figure 5A, lane 
3), suggesting that the protein-protein interaction between R06O and Ro52 does not 
require the presence of intact hY RNAs. 
Binding ofRoóO deletion mutants to Ro52 
For the characterization of the region in the R06O protein responsible for the 
interaction with Ro52, several N- and C-terminal R06O deletion mutants were used. Their 
structures are schematically shown in figure 5C. After in vitro transcription of the 
A + control +ROÍ0 pET 
1 2 3 4 1 1 3 4 
В + control + R06O pET 
1 2 3 4 1 2 3 4 
• EHI 
С + control + La pET 
1 2 3 4 1 2 3 4 
90 
Д < kDa ' 1 2 3 
»4-
«7-
В. 
ЛС419 ІСЖ ДС343 ДСЗІ« АС2Ч2 ЛСІМ 
43-
30-
М-
» * · SSf III·! 
ΛΝ27« ЛЛ ІЛ 
И), 1 + 1 + 1 » 
R 
43-
20-
= гв55 С. 
wt 
ДС419 
ДС395 
ДС343 
ДС318 
ДС292 
ДС134 
ΔΝ276 
ΔΑ 
ΔΒ 
538 
R o 5 2 RNA 
binding blndlna 
419 
] 395 
Ö43 
318 
292 
134 
276 
áj8 389 
i l _ 
276 ¿18 
putative Ro52 binding region 
Fig. 5. Protein-protein interaction between Ro52 and recombinant Ro60. 
ршкі A: In vitro transcribed and wheat germ extract translated Ro60 protein was incubated with HeLa S100 
extract and immunoprecipitated by monospecific anti-Ro52 antibody (lane 1). In lane 2 no HeLa S100 extract 
was added as a control. In lane 3, micrococcal nuclease treated HeLa S100 extract was used. Total 
immunoprecipitated protein was analyzed on an SDS-polyacrylamide gel. Input [35S]-labelled protein is shown 
in the lane marked i. pand В: Immunoprecipitation of Ro60 deletion mutants with anti-Ro52 antibody after 
incubation with HeLa S100 extract. Numbers on top of the lanes refer to the deletions as indicated in panel С 
In the lanes marked i total input [-"SJ-labelled protein was loaded, in the lanes marked + the 
immunoprecipitated proteins are shown. Molecular weight markers are indicated on the left. Panel C: 
Schematic representation of Ro60 deletion mutants. Structural features of Ro60 such as RNP-80 motif (RNA 
binding domain or RNA recognition motif, dashed area) and Zn (putative Zn-finger, filled bar) are indicated. 
Numbers on top of the bars refer to the numbers of the first or last amino acids. Results, as shown in panel В 
for the binding of RoS2 to Ro60, are indicated on the right. The putative Ro52 binding domain is indicated 
below, ranging from amino acid 276 to amino acid 318. 
truncated cDNAs and subsequent translation of the resulting mRNAs in the presence of 
[35S]-methionme, similar types of experiments were performed as described above. 
Results obtained by this method are shown in figure 5B and summarized in figure 5C. 
Most N- and C-terminal R06O deletion mutants bind the Ro52 protein with a similar 
efficiency as wild type R06O. However, Ro60AC292 and Ro60AC134 deletion mutants 
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are not capable of binding to RoS2. This suggests that a domain in R06O, spanning from 
amino acid 276 to amino acid 318, is required for the stable association of R06O with 
Ro52. This domain contains two cysteine residues of a putative zinc fìnger, suggesting a 
possible role for these cysteines in the protein-protein interaction between Ro52 and 
R06O. In another series of experiments the RNA binding ability of the R06O deletion 
mutants was examined (summarized in Figure SC). Although wild type R06O was able to 
bind to hY RNA, deletions at the N- and C-terminus of R06O completely prevented 
binding to hY RNA (results not shown; Pruijn et al., manuscript in preparation). The fact 
that some of these non-RNA binding R06O deletion mutants are still able to bind to Ro52 
is another indication for the RNA independency of the protein-protein interaction between 
both Ro proteins. 
Discussion 
Several studies have shown that in vitro reconstitution of RNA and proteins into 
RNPs is a reliable and informative way to analyze the RNA-protein and protein-protein 
interactions within ribonucleoprotein complexes (Hamm et al., 1987; Patton et al., 1987; 
Kleinschmidt et al., 1989). 
This report describes the use of an in vitro system based on the incubation of 
[32P]-labelled hYl RNA in HeLa S100 extract, that allows the specific reconstitution of 
Ro RNP complexes. Our first analyses of RNA-protein interactions within the 
reconstituted particle (Pruijn et al., manuscript in preparation) confirm earlier data of 
Wolin and Steitz (1984) concerning the binding region of R06O on the hY RNAs and 
observations about the binding region of La on RNA polymerase ΠΙ transcripts (Stefano, 
1984). In this paper we examined the association of RoS2 with Ro RNPs in more detail 
and were able to identify a direct interaction between the R06O and Ro52 antigens. 
Immunodepletion of HeLa S100 extracts either for R06O, Ro52 or La followed 
by suppletion with recombinant R06O or recombinant La demonstrated that R06O and La 
associate with Ro RNP complexes without being influenced by the presence or absence of 
one of the other known protein constituents. This proves the independent binding of R06O 
and La to hYl RNA as has been suggested recently (Boire and Craft, 1990). Although 
R06O and La seem to bind to hYl RNA directly, confirming previous reports (Wolin and 
Steitz, 1984; Deutscher et al., 1988; Moreau et al., 1990), RoS2 was only able to 
associate with hYl RNA when R06O was present in the extract. This suggests that either 
RoS2 binds to R06O or that binding of R06O induces a conformational change in hYl 
RNA enabling Ro52 to assemble with the RNP complex. Our results indicate that the first 
assumption is true. 
To further define the interaction between R06O and Ro52, [35S]-labelled R06O 
was incubated in HeLa S100 extract followed by immunoprecipitation with monospecific 
anti-RoS2 antibody. By this method Ro52 bound ["SJ-RoóO can be precipitated 
specifically and analyzed. The protein-protein interaction between R06O and RoS2 proved 
to be RNA independent, since reconstitution of Ro60-Ro52 complexes in hY RNA free 
HeLa S100 extract was equally efficient. Furthermore, R06O deletion mutants, not able to 
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Fig.6. Model for the structure of the hYl RNP. 
The sequence of hYl RNA is identical to the sequence 
published by Wolin and Steitz (1983). Secondary structure of 
hYl RNA is shown as predicted using parameters of Turner 
et al. (1988) based upon free enrgy minimizations. A similar 
though somewhat different structure has been published by 
Wolin and Steitz (1983). The binding regions of the Ro60 
and La polypeptides have been suggested by Wolin and Steitz 
(1984) and Stefano (1984), respectively, and were confirmed 
in our laboratory (Pruijn et al., submitted). 
bind hYl RNA (summarized in Figure 5c, data from Pruijn et al., submitted) are still 
able to bind to Ro52, corroborating the RNA-independency of the Ro60-Ro52 interaction. 
By performing reconstitution studies with several N- and C-terminal R06O 
deletion mutants a domain in R06O, responsible for binding to Ro52, was identified. In 
this domain, ranging from amino acid 276 to amino acid 318, two cysteine residues are 
located which are part of a putative zinc finger motif. Since Ro52 has three putative zinc 
fingers located in the N-terminal part of the protein (Chan et al., 1991) and zinc fingers 
possibly involved in protein-protein interactions have been described (see for example 
Nelissen et al, 1991), it will be interesting to know whether the zinc finger motifs of 
Ro52 indeed are involved in the interaction with R06O. 
Based upon the results described in this paper, it is possible to draw a model of 
the hYl RNP complex (Figure 6). In this model R06O binds to the lower part of the stem 
structure of hYl RNA (as uggested by Wolin and Steitz (1984) and confirmed by Prtuijn 
et al., submitted), the Ro52 protein binds to the R06O protein and is probably not in 
contact with the RNA. The La antigen binds to the 3' uridine residues (Stefano, 1984) 
and this association is not influenced by the binding of the Ro proteins. 
Although in this study only hYl RNP complexes were reconstituted, there is no 
reason to assume that the interactions in other hY RNPs concerning the Ro and La 
antigens will be very different. Immunoprecipitation of in vivo labelled Ro RNP particles 
with either monospecific anti-Ro60 or anti-Ro52 antibody yield identical RNA patterns 
(Slobbe et al, 1991b), indicating that both antigens are contained in the same subset of hY 
RNPs. However, it is possible that R06O, Ro52 and La are the common or "core" Ro 
RNP proteins and that other yet unknown proteins may be part of subsets of Ro RNP 
complexes. For example, it has been reported that at least three different groups of Ro 
RNPs with different physicochemical properties and molecular weights of about 230 kDa 
(hY4) and 300-350 kDa (hYl-4, hY5) exist in human cells (Boire and Craft, 1990). The 
high molecular weights of these complexes may be caused by the existence of multimers 
of proteins or particles or by the binding of yet unidentified Ro RNP components. In 
addition, human sera have been described that precipitate the hY5 RNP particle only 
hYl RNP 
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(Boire and Crañ, 1989) indicating the presence of a unique antigenic determinant on this 
subset of Ro complexes. 
Further characterization of the complexity of Ro RNP complexes both in vivo and 
in vitro will help to elucidate the molecular composition of the Ro particles and may give 
clues to the functíon(s) of these ribonucleoprotein complexes. 
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Chapter 7: 
Survey and Summary 

Survey and Summary 
For some yet unknown reason patients with rheumatic diseases develop antibodies 
against self-components. These so-called autoantibodies frequently target proteins that are 
complexed with RNAs in ribonucleoprotein particles. It is obvious that such 
autoantibodies can be of great use in the characterization of the antigenic complexes and 
the determination of their cellular function. 
In this thesis autoantibodies frequently found in sera from patients with systemic 
lupus erythematosus (SLE) and Sjogren's syndrome (SS) were used to study the molecular 
composition and antigenicity of one subclass of RNA-protein particles, the Ro RNP 
complexes. These complexes consist of a small RNA molecule (in human cells four Ro 
RNAs have been identified, referred to as hYl, hY3, hY4 and hY5) complexed with at 
least three proteins, the La protein and two Ro proteins of 60kDa (R06O) and 52 kDa 
(Ro52). No function has been found yet for these relatively abundant RNA-protein 
particles. 
Since most patient sera contain multiple antibody specificities (anti-Ro and anti-
La antibodies mostly are found together in patient sera) and good monoclonal antibodies 
directed against the Ro and La antigens are rare, a sensitive assay had to be developed to 
test patient sera for the presence of anti-Ro and anti-La antibodies in order to find 
monospecific sera that could be used in our studies. Therefore, in Chapter 3 a method 
for the analysis of patient sera is described based upon the precipitation of ["PJ-labelled 
RNA from adenovirus infected HeLa cells. By this test anti-La antibodies can be 
demonstrated in very low titers, whereas anti-Ro antibodies can be detected 
simultaneously. It was shown that patient sera presumed to be monospecific for anti-Ro 
antibodies by other techniques frequently contain trace amounts of anti-La antibody. 
Furthermore, in this chapter it was shown that the synthesis of Ro RNAs proceeds at 
normal levels after adenovirus infection, whereas other cellular RNAs like the U RNAs 
are no longer transcribed. Since most cellular processes become arrested after adenovirus 
infection, this could mean that the Ro RNPs have an essential function for the propagation 
of the virus and have to be synthesized continuously in order to fulfil this function. 
In Chapter 4 the antigenicity of the different components in Ro RNP complexes 
was investigated. In order to detect RoS2 by immunoblotting the crosslinking level of the 
SDS-PAGE gelsystem was lowered to an acrylamide to bisacrylamide ratio of 19 to 1 to 
enable the separation of Ro52 from La. This allowed the simultaneous detection of anti-
R06O, anti-Ro52 and anti-La antibodies in a patient serum. By analysis of sera from 
patients with SLE and SS it was found that anti-Ro60 antibody without anti-Ro52 or La 
antibodies is indicative for SLE, whereas the presence of anti-Ro52 and anti-La antibodies 
without anti-Ro60 antibody is of diagnostic value for SS. In addition, the association of 
RoS2 in Ro RNP complexes was studied m vivo. It appeared that both R06O and Ro52 
bind to hYl, hY3, hY4 and hY5 RNA and co-localize in the cytoplasm as well as in the 
nucleus as determined by double immunofluorescence techniques, indicating a close 
relationship between these two proteins. Furthermore, the evolutionary conservation of 
the Ro and La proteins was studied by immunoblotting. Although R06O and La seem to 
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be well conserved during evolution, Ro52 could be detected immunologically in primate 
cells only. At this moment, it is not clear whether the selective reactivity of anti-Ro52 
antibodies with primate antigen reflects the alteration of the antigenic determinants of 
Ro52 during evolution or is due to the absence of a related protein in non-primates. In the 
Appendix of this chapter the evolutionary conservation of the Ro RNAs is studied by 
incubating Northern blots with antisense Y RNA probes. Although Yl and Y3 RNAs 
seem to be generally present in all mamalian species studied, Y5 RNA seems to be absent 
in rodent and bovine cells. This may reflect possible different cellular functions of the 
various Ro RNP particles. 
For the determination of the function of the Ro particles it is essential to 
understand the composition and complexity of the RNPs. To elucidate (part of) the 
interactions in Ro RNP particles a number of the components of these complexes were 
cloned, i.e. the cDNAs encoding R06O and La and the sequences coding for hYl, hY3 
and hYS, as described in Chapter 5. By using various in vitro reconstitution techniques it 
was demonstrated that the conformation of R06O presumably is important for the 
interaction with Y RNA, since no N- or C-terminal deletions of the protein were allowed 
for RNA binding. For binding of La to Y RNA it was shown that the RNP-80 motif and 
sequences at the N-terminus of this motif were required. In addition, the regions on the 
RNAs that interact with the Ro and La antigens were analyzed. It was shown that the 
among Y RNAs highly conserved nucleotides at the lower part of the stem determine the 
interaction with both Ro proteins, indicating that R06O and Ro52 either bind to the RNA 
in the same region or that Ro52 needs R06O for binding, whereas the 3' end of the RNAs 
is involved in the binding of La. 
In order to identify possible protein-protein interactions in Ro RNP complexes, in 
Chapter 6 HeLa cell extracts were prepared from which one of the proteins involved in 
Ro RNP complexes had been removed by immunodepletion. Subsequent reconstitution of 
Ro RNP complexes revealed that the absence of the Ro proteins had no effect on the 
binding of La to hYl RNA and vice versa. However, the absence of R06O completely 
prevented Ro52 from binding to hYl RNA. Supplementation of recombinant R06O in 
R06O depleted extract restored both the binding of R06O and Ro52 to hYl RNA, 
indicating that the presence of R06O is essential for the binding of Ro52 to Ro RNP 
complexes. In addition, a direct RNA-independent protein-protein interaction between 
R06O and Ro52 was identified. For this interaction a region of R06O between amino acids 
276 and 318, which contains two cysteine residues of a putative zinc finger structure, is 
important. 
Although in this thesis many questions remain unanswered it is evident that the 
elucidation of the molecular interactions in Ro RNP complexes in vitro may contribute to 
the understanding of both the structure and function(s) of the Ro particles in vivo. 
Furthermore, unraveling the complexity of Ro RNP particles may aid to a better 
understanding of the molecular basis of autoimmunity. 
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Samenvatting 
Om nog onopgehelderde redenen maken patiënten met rheumatische 
aandoeningen antilichamen tegen lichaamseigen componenten. Deze zogenaamde auto-
antilichamen zijn vaak gericht tegen eiwitten die gebonden zijn aan RNA in eiwit-RNA 
(RNP) complexen. Het is duidelijk dat deze antilichamen van grote waarde kunnen zijn 
voor de karakterisatie van de antigenen en voor de bepaling van hun functie in de cel. 
In dit proefschrift worden auto-antilichamen, vaak voorkomend in sera van 
patiënten met systemische lupus erythematosus (SLE) en Sjogren's syndroom (SS), 
gebruikt ter bestudering van de samenstelling en antigeniciteit van een subklasse van 
eiwit-RNA partikels, de Ro RNP complexen. Deze complexen bestaan uit een klein RNA 
molekuul (in humane cellen zijn vier RNAs geïdentificeerd, genoemd hYl, hY3, hY4 en 
hYS) gebonden aan tenminste drie eiwitten: het La eiwit en twee Ro eiwitten van 
respektìevelijk 60 kDa (R06O) en 52 kDa (Ro52). Tot nu toe is van deze in de cel relatief 
veel voorkomende RN A-eiwit partikels nog geen functie bekend. 
Aangezien de meeste patienten-sera antilichamen bevatten gericht tegen meerdere 
antigenen (anti-Ro en anti-La antilichamen komen meestal samen voor in patienten-sera) 
en goede monoklonale antilichamen gericht tegen de Ro of La antigenen zeldzaam zijn, is 
een gevoelige test ontwikkeld om patienten-sera te testen op de aanwezigheid van anti-Ro 
en anti-La antilichamen teneinde monospecifieke antisera te vinden die gebruikt kunnen 
worden in andere studies. In Hoofdstuk 3 wordt een methode beschreven voor de analyse 
van patienten-sera gebaseerd op de immunoprecipitatie van ["PJ-gelabeld RNA uit 
adenovirus-geïnfekteerde HeLa-cellen. Door deze test kunnen zeer lage titers anti-La 
antilichamen maar ook anti-Ro antilichamen gedetecteerd worden. In dit hoofdstuk wordt 
aangetoond dat patienten-sera waarvan op grond van andere technieken aangenomen werd 
dat deze monospecifiek waren voor anti-Ro antilichamen toch vaak zeer kleine 
hoeveelheden anti-La antilichamen bevatten. Verder wordt in dit hoofdstuk beschreven dat 
de Ro RNAs na adenovirus-infektie nog steeds worden aangemaakt, terwijl andere RNAs 
zoals bijvoorbeeld de U RNAs niet langer getranscribeerd worden. Aangezien een groot 
aantal cellulaire processen worden stilgelegd na adenovirus-infektie betekent dit dat de Ro 
RNPs waarschijnlijk ook een belangrijke funktie hebben bij de aanmaak van nieuwe virus-
partikels en continu gesynthetiseerd dienen te worden om deze funktie uit te kunnen 
voeren. 
In Hoofdstuk 4 is de antigeniciteit van de verschillende componenten van Ro 
RNP complexen onderzocht. Om Ro52 te detecteren met behulp van immunoblotting en 
het te kunnen scheiden van het La antigen is het niveau van cross-linking in het SDS-
PAGE gelsystem verlaagd naar een acrylamide: bisacrylamide verhouding van 19: 1. Dit 
maakte een gelijktijdige detectie van anti-Ro60, anti-Ro52 en anti-La antilichamen in 
patienten-sera mogelijk. Na analyse van een aantal sera van SLE en SS patiënten bleek 
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dat de aanwezigheid van anti-Ro60 zonder antì-Ro52 of anti-La antilichamen in een 
patienten-serum een sterke aanwijzing is voor SLE, terwijl aan de aanwezigheid van anti-
RoS2 en anti-La zonder anti-Ro60 antilichamen de diagnose SS gekoppeld kon worden. 
Bovendien is de associatie van Ro52 met Ro RNP complexen in vivo bekeken. Het bleek 
dat R06O en Ro52 beide binden aan hYl, hY3, hY4 en hY5 RNAs en co-lokaliseren in 
cytoplasma en kem wanneer dat bepaald werd met behulp van de dubbele 
immunofluorescentie techniek, wat duidt op een nauwe verwantschap tussen beide 
eiwitten. Verder is de evolutionaire conservering van de Ro en La eiwitten bestudeerd 
met behulp van immunoblotting. Alhoewel R06O en La goed geconserveerd lijken te zijn 
in de evolutie, kon Ro52 allen maar aangetoond worden in cellen van primaten. Het is nu 
nog niet duidelijk of de selektieve reaktie van anti-Ro52 antilichamen met primaat 
antigenen wordt veroorzaakt door de evolutie van de antigene determinanten van Ro52 of 
door de afwezigheid van een verwant eiwit in niet-primaten. In de Appendix van dit 
hoofdstuk is de evolutionaire conservering van de Ro RNAs bestudeerd door het 
incuberen van Northern blots met anti-sense Y RNAs. Alhoewel Yl en Y3 RNAs in alle 
zoogdieren aantoonbaar waren, lijkt het Y5 RNA afwezig te zijn in knaagdier en in 
runder cellen. Het lijkt dan ook mogelijk dat de verschillende Ro RNP partikels een 
verschillende cellulaire functie hebben. 
Voor de bepaling van de funktie van de Ro RNP partikels is het van groot belang 
om de complexiteit en samenstelling van de RNPs te ontrafelen. Om (een gedeelte van) de 
interakties in Ro RNP partikels op te helderen zijn een aantal componenten van de 
complexen gekloneerd, namelijk de cDNAs coderend voor R06O en La en de coderende 
sequenties van de hYl, hY3 en hY5 genen, zoals beschreven in Hoofdstuk 5. Door 
gebruik te maken van diverse in vitro reconstitutie technieken kon aangetoond worden dat 
de conformaüe van R06O waarschijnlijk belangrijk is voor de interaktie met Y RNA, 
aangezien kleine N- of C-terminale deleties de binding van deze R06O deletie mutanten 
aan het RNA verhinderden. Voor de binding van La aan Y RNA bleken het RNP-80 
motief en sequenties N-terminaal hiervan essentieel te zijn. Bovendien zijn in dit 
hoofdstuk de regio's op het RNA gekarakteriseerd die een interaktie aangaan met de Ro 
en La antigenen. De bij Y RNAs sterk geconserveerde nucleotiden onder aan de 
stamstruktuur bleken belangrijk voor de interaktie met beide Ro eiwitten. Dit duidt erop 
dat ofwel R06O en Ro52 beide binden aan het RNA op dezelfde plaats ofwel dat Ro52 
R06O nodig heeñ voor binding. Het 3' einde van de RNAs bleek betrokken te zijn bij de 
binding van La. 
Om mogelijke eiwit-eiwit interakties in Ro RNP complexen aan te tonen zijn in 
Hoofdstuk б HeLa extracten gemaakt waaruit één van de Ro RNP eiwitten is verwijderd 
door immunodepletie. Reconstitutie van Ro RNP complexen in zulke extracten toonde aan 
dat de afwezigheid van Ro eiwitten geen effect heeft op de binding van La aan hYl RNA 
en vice versa. Echter, de afwezigheid van R06O verhinderde de binding van Ro52 aan Y 
RNA. Aanvulling van Ro60-gedepleteerd extract met recombinant R06O herstelde zowel 
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de binding van R06O als van RoS2 aan hYl RNA, wat een aanwijzing is voor het feit dat 
de aanwezigheid van R06O essentieel is voor de binding van RoS2 aan hYl RNA. 
Bovendien is een direkte, RNA-onafhankelijke eiwit-eiwit interaktie aangetoond tussen 
R06O en RoS2. Een gebied van het Ro60-molecuul tussen aminozuur 276 en 318, welke 
twee cysteine residuen van een mogelijke zink fìnger bevat, blijkt belangrijk te zijn voor 
deze R06O/R0S2 interactie. 
Alhoewel in dit proefschrift veel vragen onbeantwoord blijven is het toch 
duidelijk dat de opheldering van de molekulaire interakties in Ro RNP complexen in vitro 
kan helpen bij het begrijpen van zowel de stniktuur als de funktie(s) van Ro partikels in 
vivo. Bovendien kan de opheldering van de complexiteit van Ro RNP partikels bijdragen 
tot een beter begrip van de molekulaire basis van autoimmuniteit. 
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